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ABSTRACT 
Delayed onset muscle soreness (DOMS) is muscle pain that arises 24-72 hours after exercise 
involving unfamiliar strenuous muscle loading. DOMS is commonly induced by eccentric muscle 
contractions and may signify exercise-induced muscle damage including impaired excitation-
contraction coupling and injury to cytoskeletal proteins in the sarcomere. During DOMS, muscle 
pain is transmitted via A-delta and C-fibre afferents (group III/IV afferents) to the central nervous 
system (CNS). While it has been shown that muscle force production is significantly diminished 
in DOMS, there is limited evidence on the influence of DOMS on corticospinal excitability or 
inhibition. Furthermore, to date no work has investigated how the application of topical analgesic 
interacts with DOMS to modulate corticospinal excitation. The current thesis employed a model 
of DOMS involving fatiguing eccentric elbow flexor contraction exercise. We investigated the 
effect of DOMS on indices of corticospinal excitability (motor evoked potential [MEP] and 
cervicomedullary evoked potential [CMEP] area and latency) and inhibition (silent period), 
peripheral motor excitability (Mmax area and latency), and pain pressure threshold (PPT) in the 
dominant biceps brachii muscle, as well as how application of a menthol-based topical analgesic 
(Biofreeze®) influenced these outcomes. Two experiments were employed to test the effects of 
topical analgesic in participants with and without DOMS. In the first experiment (Experiment A: 
No DOMS), 16 young healthy adults (F = 8, M = 8; age = 23 ± 1.1 yr; body mass = 71.9 ± 9.1 kg; 
height = 174.2 ± 8.2 cm) were randomly allocated to receive either a menthol-based topical 
analgesic gel (Topical Analgesic, n = 8) or a placebo gel (Placebo, n = 8) in a double-blind fashion, 
during a single session; DOMS was not induced. Prior to the application of gel (pre-gel), as well 
as 5 (post-5 min), 15 (post-15 min), 30 (post-30 min), and 45 (post-45 min) minutes after the 
application of gel, MEP area, latency, and silent period; CMEP area and latency; and Mmax area 
 3 
and latency were measured. Participants’ MEP and CMEP areas were normalized to Mmax area. 
Neither group showed a statistically significant change in these outcome measures at any post-gel 
time-point compared to pre-gel (p > .05). In the second experiment (Experiment B: DOMS), 16 
young healthy male adults (age = 26 ± 5.1 yr; body mass = 81.9 ± 9.1 kg; height = 179.8 ± 6.1 cm) 
completed two experimental sessions. During the first session participants completed a fatiguing 
eccentric elbow flexor contraction protocol to induce DOMS. Participants returned 48 hours later 
and were randomly allocated to Topical Analgesic (n = 8) or Placebo (n = 8) in a double-blind 
fashion. During the second session MEP area/Mmax area, MEP latency, silent period, CMEP 
area/Mmax Area, CMEP latency, Mmax area, and Mmax latency were measured at the same time-
points as above. Additionally, PPT was measured during session one (pre-DOMS), as well as at 
the above time-points. Both groups exhibited a statistically significant decrease in PPT from pre-
DOMS to pre-gel (Topical Analgesic, pre-DOMS = 7.03 ± 2.48 kg, pre-gel = 3.12 ± 1.26 kg, p 
<0.001 Placebo, pre-DOMS = 5.77 ± 2.35 kg, pre-gel = 3.51 ± 1.58 kg, p = .005). Following the 
application of gel there was a significant increase in PPT at post-15 min (3.70 ± 1.69 kg, t(7) = -
2.619, p = .034), post-30 min (3.92 ± 1.67 kg, t(7) = -3.987, p = .005), and post-45 min (4.33 ± 1.65 
kg, t(7) = -4,566, p = .003) compared to pre-gel (3.12 ± 1.26 kg) in the Topical Analgesic group 
only. Under the Placebo group, there was no statistically significant change in PPT values (p > 
.05). Regarding neurophysiological changes there was a statistically significant increase in silent 
period compared to pre-gel (85.67 ± 19.65 ms) at both post-30 min (96.08 ± 26.62 ms, p = .045) 
and post-45 min (94.23 ± 22.32 ms, p = .029), in the Topical analgesic Group. The Placebo group 
did not exhibit a statistically significant change in silent period at any time-point (p > .05). No 
other measures of corticospinal (MEP area/Mmax area, MEP latency, CMEP area/Mmax area, 
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CMEP latency) or peripheral motor excitability (Mmax area, Mmax latency) were significantly 
different after the application of topical analgesic or placebo gel (p > .05).  
When comparing pre-gel neurophysiological outcomes in participants from Experiment A: 
No DOMS (n = 16) and Experiment B: DOMS (n = 16), there were statistically significant 
differences in MEP area/Mmax area (Experiment A = 0.222 ± 0.169; Experiment B = 0.097 ± 
0.057, p = .011), CMEP area/Mmax area (Experiment A = 0.186 ± 0.148; Experiment B = 0.077 ± 
0.045; p = .012), and silent period (Experiment A = 77.41 ± 31.05 ms; Experiment B = 100.85 ± 
32.29 ms; p = .045). No other neurophysiological measures were significantly different across 
experiments (p > .05). The present findings suggest that DOMS imposes changes in the 
neuromuscular system that result in increased pain, reduced corticospinal excitability, and elevated 
corticospinal inhibition. Following the administration of menthol-based topical analgesic, but not 
a placebo gel, there is a reduction in pain which is accompanied by further increases in 
corticospinal inhibition. These results provide novel information on the neurophysiological effects 
of DOMS, as well as the influence on topical analgesic on DOMS-induced neurophysiological 
changes. 
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CHAPTER 1 – REVIEW OF LITERATURE 
1.1 Introduction 
This literature review gives a brief overview of the current methods used to evoke and 
assess pain, the ways that pain is measured and the procedures used to assess corticospinal 
excitability. There is an interaction between sensory inputs and motor outputs from the cortex and 
spinal cord. These interactions are complex and while not completely understood they will be 
reviewed along with some of the methods used to assess these complex interactions. Also, 
techniques to attenuate painful input and the potential effect on corticospinal output will be 
highlighted. Finally, the physiology behind the effect of the topical analgesic menthol will be 
explored along with its effects on pain and motor output. Hopefully by understanding the flaws 
and limitations in the current methodologies as well as what’s known about the etiology of pain 
and analgesics on the nervous system, it will allow us to produce better methods for testing and 
assessing pain and its influence on the corticospinal tract leading and subsequent motor output. 
1.2 Physiology of Pain 
Pain is a complex process initiated by stimulation of peripheral nociceptive receptors and 
summated as conscious perception in the cerebral cortex. The sensation of pain in skeletal muscle 
is transmitted by large thinly myelinated group III (A-delta fibre and small unmyelinated group IV 
(C-fibre) afferents. Both of these sensory neurons terminate in free or unencapsulated nerve 
endings predominantly found in the interstitial fluid and connective tissue between muscle fibres, 
with their cell bodies in the dorsal root ganglia. The A-delta fibres, believed to transmit sharp, 
prickling, stabbing type pain, are predominantly activated by mechanical deformation of tissue. 
The C-fibres, which carry dull cramping pain are predominantly activated by a noxious chemical 
environment [Marchettini, Simone [1]]. Chemical substances that elicit action potentials in these 
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fibres include bradykinin, serotonin, histamine, prostaglandin and potassium. These are released 
by various sources including white blood cells, macrophages and platelets, which can be stimulated 
by skeletal muscle activity [2]. The type III and IV afferents synapse with neurons in the dorsal 
horn of the spinal cord. Wide dynamic range neurons are located in laminae five and respond to 
many types of stimuli, whereas nociceptive specific neurons located more superficially in lamina 
one and two, respond preferentially to noxious stimuli. The major neurotransmitter for injurious 
input in the spinal cord is glutamate but many other molecules can stimulate nociceptive neurons. 
From the dorsal horn these nociceptive signals are transmitted via a number of ascending tracts, 
which first synapse to pain relevant brainstem areas involved in emotion, cardiorespiratory 
regulation, sensory perception and movement. The impulses are then relayed too multiple 
subcortical and cortical regions involved in integration of the sensory, emotional and cognitive 
aspects of pain, confirming the multidimensional landscape of the human pain experience. For a 
further comprehensive review see Millan et al. [3]. 
1.3 Experimental Pain 
The assessment of pain is a major challenge in both laboratory and clinical settings. It is 
difficult to evaluate the effect of pain on human performance due to the complex nature of its 
interactions with the nervous system. Furthermore, the mechanisms underlying pain are poorly 
understood. To help improve this lack of understanding, human experimental pain models have 
been developed to provide a way to explore the physiological effects of pain and its effect on 
human performance under controlled settings. The mechanisms of induced experimental pain can 
be broken down into three different categories based on the area of stimuli, including pain evoked 
in the skin, muscles and visceral areas. Pain models that originate around the skin are induced by 
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thermal, electrical, mechanical and chemical stimuli, and all have been well developed due to the 
easy accessibility of the skin [4]. 
1.3.1 Thermal stimulation 
 The use of cold thermal stimulation through the immersion of an extremity in ice saturated 
water for one to two minutes at a temperature between 0-2 degrees Celsius has been found to 
activate nociceptive afferents [4]. The nociceptive input is proposed to originate in cutaneous veins 
and has been termed cold pressure pain that has been shown to activate both A-delta and C fibres 
[4]. Limitations to studying this type of stimulation have mostly been demonstrated in the 
assessment of vascular reacting analgesics. The testing of these drugs have produced conflicting 
results because any vasodilation or constriction would affect the perception of pain mechanistically 
and not actually block the pain from being perceived [5]. This alteration in pain perception would 
affect the reliability of the results as any changes found may be due to differences between 
participants pain perception [6]. Another method commonly used to invoke thermal stimulation is 
contact heat, often applied from a Peltier thermode or heat foil. The rapid heating of the skin can 
also activate both A-delta and C fibres, with A-delta activated first followed shortly thereafter by 
C fibres [7]. One of the major limitations with the use of contact heat is concomitant activation of 
nociceptors and non-nociceptive low threshold sensory receptors. These receptors can be activated 
by mere contact of the thermode to the skin. By activating other afferent nerves, you potentially 
inhibit the influence of the pain afferents or at least make their effect undistinguishable from 
afferent information as a whole  [8]. Radiant heat, however, has been the preferential method of 
inducing thermal stimulation. Radiant heat is most commonly used to cause experimental pain 
through laser pulses. These pulses cause a pricking pain in the skin. Again pain evoked by laser 
stimulation has been shown to be mediated through A-Delta and C-fibres [9]. A major advantage 
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to this technique is the fact that the stimulus does not require any contact with the skin, avoiding 
the problem associated with contact heat. However, reflectance absorption and transmission can 
vary from participant to participant based on skin pigmentation, so the required intensity to reach 
the threshold for pain can be highly variable [8, 9]. This could be somewhat remedied by finding 
participants with a similar skin tone, however, in turn you would be effecting external validity with 
this kind of participant selection bias [6]. 
1.3.2 Electrical Stimulation 
 A variety of electrical stimulation devices can be hooked up to electrodes and placed on 
the surface of the skin. In turn, a variation of different stimulation intensities and durations can be 
given to any area of the body. This allows researchers to have some selectivity on which afferent 
fibres are activated [10]. However, electrical stimulation in some cases may bypass the specific 
afferents associated with nociception and activate nerves directly, thus decreasing the external 
validity of the measure by poorly representing a clinical or practical setting [6, 11]. The act of 
stimulating the afferent nerves directly, although the most common, is not the only use of electrical 
stimulation to elicit experimental pain. Electrical stimulation can be applied directly into the 
muscle or the viscera. In order for the technique to be applied directly to the muscle the researchers 
require small needle electrodes with un-insulated tips  [12]. Stimulation of the viscera with this 
method has the added drawback of being an even more invasive procedure. Stimulation of the 
viscera is often used for determining basic pain mechanisms and neurophysiological assessments 
[13, 14].  
1.3.3 Chemical Stimulation 
Capsaicin is one of the most commonly used methods of chemical stimulation. It is applied 
through intradermal injection or placement of topical capsaicin cream. The application is intended 
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to trigger primary and secondary hyperalgesia. The use of 100 microliters evokes a burst of pain 
that is short lived and is regionalized to injection or the topical sites. It has been speculated that 
mostly C-fibres are involved in the pain induced by capsaicin [15]. Limitations of this method are 
unclear and studies that examine this method have found differing results. For example when 
Wallace et al. [15] tested the effect desipramine, a clinically proven treatment of neuropathic pain, 
to block capsaicin induced pain, there were no beneficial effects. In contrast, when Dirks et al. [16] 
tested another neuropathic pain pharmaceutical agent, gabapentin, suppression of hyperalgesia 
following heat-capsaicin sensitization was found. 
1.3.4 Muscle Pain Via Hypertonic Solution Injection 
Another method of experimental chemical pain stimulation can be achieved by infusing 
algogenic substances into the muscles. This injection mimics the inflammation and effects on 
performance that are often associated with DOMS [17]. Injection of hypertonic saline has also 
become a widely accepted methodology due its ability to mimic the effect of DOMS. Hypertonic 
saline activates the nociceptive afferents within the muscle fibre and bypasses sharper and more 
distinct pain sensory fibres in this skin [18]. Injection of saline has a closely related etiology to 
musculoskeletal pain both in its effects on motor performance and subjective quality [19, 20]. C -
afferent fibres are activated by these saline injections and are perceived as a dull deep pain. 
Reliability can be an issue when using this type of methodology for experimental pain as the 
interindividual differences are large [21]. 
1.3.5 Muscle Pain Via Delayed Onset Muscle Soreness 
Muscle pain can also be induced through unfamiliar strenuous muscle loading exercise, 
arising 24-72 hours post exercise (i.e. DOMS). The response is most commonly brought about by 
eccentric muscle contractions and signifies that there has been muscle damage. Muscle pain 
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associated with DOMS is transmitted via A-delta and C afferent fibres and has a very high external 
validity, as this is one of the most common forms of pain experienced in everyday life. The major 
limitation that comes with the induction of muscle pain is the fact that not all participants will 
reliably get DOMS after exercise. Pain associated with DOMS will be described in more detail in 
Section 1.5.  
1.4 Measurement of Pain 
Some of the most common ways that pain is quantified is via verbal descriptor or visual 
analogue scales (VAS), and in the case of muscle pain, a technique termed pressure-pain threshold 
(PPT). The verbal descriptor scale is a technique in which the participants are presented with a 
number of words and are told to choose the one which best matches the pain they are feeling. The 
VAS has the participant rate pain on a scale of 1-10 [22]. Both these techniques have a drastic 
problem with participant reactivity [6], as the participant may rank the pain lower than actually 
experienced due to the presence of the researcher. Pain Pressure threshold is a measurement of 
tenderness over a specific area of the body. Using a pressure algometer, the researcher applies 
pressure to the place of interest of the participant, who then identifies when a perceived sensation 
of pressure changes into a sensation of pain. This method has been shown to produce accurate, 
valid and reproducible results [23-27]. However, the method can have improved reliability if an 
average of multiple trials is performed. This yields a better estimation of relative tenderness [28]. 
To further improve reliability, it has been suggested that the first trial measurements be discarded 
and the average of 5 trials (minimum) should be taken [29].  
1.5 Delayed Onset Muscle Soreness  
 The concept of DOMS first originated in 1900 in an article ‘Ergographic studies in 
muscular fatigue and soreness’, by Theodore Hough [30] The main findings were the appearance 
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of muscle soreness eight hours to four days post ergograph (spring weighted) experiments, and 
that the soreness elevated to its highest point twelve or more hours post testing. Hough also found 
that if he ran the resistance protocol again when the soreness was present, the discomfort would 
dissipate within five to ten minutes of the experiment. Today DOMS is described as muscle pain 
and stiffness arising 24-72 hours after strenuous, weight-loaded exercise which is unfamiliar to the 
participant [31], with the “peak” of the soreness appearing around the 48 hour time point, based 
on indicators such as largest reduction in range of motion, increase in subjective pain measures 
and muscle volume [32, 33]. DOMS is considered to indicate muscle damage brought about by 
exercise, but differs from the pain associated with muscle fatigue that occurs during or immediately 
following exercise. The exact etiology of DOMS is not fully understood, however, almost all 
research surrounding the topic agrees that it is most commonly initiated by eccentric exercise, as 
shown in studies that have examined the association between muscle pain and isometric, eccentric 
and concentric contractions, as well as static activities [31, 34]. Eccentric exercise results in greater 
disruption to muscle tissue than concentric exercise as fewer motor units are required to generate 
equal muscle force. As a result, tension is created over a smaller area, which could cause 
mechanical disruption in the muscle fibres or connective tissue components [31].  However, it has 
not been proven that injury to muscle cells is the definite mechanism which generates DOMS. In 
fact, one histological study showed myofibril and cytoskeletal remodelling and not damage which 
occurred in DOMS affected muscles [35]. Since DOMS first appeared in the literature, many 
theoretical mechanisms have been proposed to explain its origin. These mechanisms include 
mechanical muscle damage, muscle spasm, cellular inflammation, lactic acid build-up, damage to 
connective tissue, enzyme efflux and myofibrillar and cytoskeletal remodeling theories. It is more 
probable, however, that DOMS arises from a combination of these mechanisms.  
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1.5.1 Increased Lactic Acid Accumulation  
Lactic acid accumulation theory has been mostly discarded as one of the mechanisms that 
leads to DOMS. Increased lactic acid accumulation during or immediately following an intense 
bout of exercise can cause acute pain, but this mechanism cannot be confirmed as a significant 
contributing factor towards delayed soreness.  For example,  an experiment by Schwane et al. [36]  
showed that muscle lactic acid returns to pre-test measures within 60 minutes following exercise. 
Also, they found no correlations between blood lactate levels and muscle soreness over a 72-hour 
period after exercise  
1.5.2 Muscle Spasms 
The muscle spasm theory speculates that there may be hyperactivity within the resting 
muscle following bouts of exercise [37-39]. Hyperactivity results in tonic muscle spasms which 
compress local blood vessels, causing a decreased blood flow to the muscle and accumulation of 
waste products and enzymes within and around the muscle. This accumulation stimulates pain 
receptors at the site of muscle damage. The research behind this mechanism has been controversial, 
with no increase in EMG activity (which would represent a muscle spasm) in sore muscles found 
from a few studies [40, 41], while others have shown the opposite [42, 43]. Even if the EMG 
research results were consistent, no relationship has been found to correlate the magnitude of EMG 
muscle hyperactivity and muscle soreness [38]. Along with the lactic acid theory, the muscle 
spasm theory has largely been rejected due to the inconsistency in results. 
1.5.3 Muscle Tissue Damage 
The muscle damage theory was first proposed by Hough [44], attributing the sensation of 
DOMS to be due to the disruption of the contractile components of the muscle, particularly seen 
at the z-line following eccentric contractions [42, 45-48]. As this area has been seen to be the 
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weakest portion of the contractile unit of the muscles [48], disruption of the z-line would be the 
primary location of structural damage in the myofibril and sarcomere [49]. Type II fibres have 
weaker and narrower z-lines and eccentric exercise favors the activation of Type II fibres. 
Therefore, this mechanistic theory could explain why eccentric exercise leads to increased DOMS 
and is supported by muscle biopsy findings [50]. 
1.5.4 Connective tissue Damage 
The connective tissue theory focuses mainly on connective tissue casing surrounding the 
muscle fibres, termed myofascia  [49]. After exercise the majority of DOMS is experienced near 
the myotendinous junction, the distal portion of the muscle belly [51]. This area contains a large 
amount of connective tissue relative to muscle tissue. As stated previously it is clear that eccentric 
exercise results in greater likelihood of DOMS and eccentric movements primarily target type 2 
muscle. Type II muscles fibres have weaker connective tissue than Type I fibres and therefore 
would be more susceptible to stretch induced connective tissue damage due to greater stress in 
eccentric exercise [37, 44, 52]. This damage would stimulate mechanoreceptors, leading to the 
sensation of pain [53]. Hydroxyproline (OHP) is a specific marker of connective tissue breakdown. 
48 hours after exercise OHP levels are the highest  [40], which correlates strongly with perception 
of muscles soreness post-exercise  [49, 54].  
1.5.5 Enzyme Efflux 
During exercise, metabolites are released into the extracellular space due to increased fibre 
degradation [45]. Two common metabolites, calcium and creatine phosphokinase, have been found 
to build up during eccentric exercise and are well established as indicators of muscle damage. 
Calcium is found in the sarcoplasmic reticulum of the muscle cell and if muscle is broken down it 
will release calcium directly. Extracellular calcium is therefore thought to be a direct indicator of 
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muscle damage [37, 45]. The accumulation of metabolites such as calcium have been shown to 
activate proteases and phospolipidases, which assist in protein degradation. This could cause even 
weaker z-lines [55]. Due to the increased tissue breakdown and metabolite release it is likely that 
nerve endings may be sensitized through chemical stimulation which would increase pain 
sensation.  
1.5.6 Inflammation 
In order to deal with metabolite release and protein/cellular degredation that occurs during 
muscle damage, inflammatory cells migrate into the affected area. Also, the build-up of  histamine, 
kinins, prostaglandins, and potassium [45] attracts monocytes and neutrophils to the damaged area 
[56]. All of this results in worsening the edema [57]. As a result of the ionic gradient change, fluid 
from inside the muscle cell will osmose to the extracellular space, resulting in increased osmotic 
pressure. This increase will stimulate type IV sensory neurons. Research has shown that with the 
increase of osmotic pressure, monocytes and macrophages secrete substances that increase the 
sensitivity of type III and type IV sensory neurons causing increased pain sensation [45, 57]. 
 
1.6 The Effect of DOMS on Human Performance 
After a bout of intensive unaccustomed exercise, DOMS will occur over a period of 24-72 
hours, peaking around the 48 hour time period and eventually dissipating within 5-7 days. The 
structural damage and soreness to both the muscles and connective tissue may result in altered 
muscle function and joint mechanics [58]. This damage can result in performance impairments 
over this time period. Neuromuscular impairments such as altered joint kinematics and functional 
impairments are prominent. A loss in muscular strength [59], force perception [60], joint angle 
perception, maximal voluntary contraction [59, 61-64],  decrease in muscle activation and 
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increased EMG to force ratios can all be attributed to a loss in proprioceptive functioning in the 
days following exercise [65]. Although these functional impairments do correlate with the onset 
and progression of DOMS, it is important to note that they each go through their own time course. 
For example impairment of  isometric muscular strength has been seen to peak around the 3-5 day 
range and take anywhere from 33 to 89 days to fully recover [66]. Functional impairments such as 
perception of force and joint position are well researched and believed to be initiated from 
peripheral receptors in Golgi tendon organs and muscle spindles [67-69]. In contrast, DOMS 
originates at the muscle belly. This represents  a possible  explanation for the differing time courses 
between function impairments and DOMS.  For a more comprehensive  review on effects of 
muscle damage on motor performance see Byrne et al. [70]. 
1.7 Topical Analgesic 
 Menthol is a naturally occurring ligand for transient receptor potential member 8 (TRMP8). 
In its normal state, TRPM8 permits the flow of ions, usually calcium or potassium, through cellular 
membranes where they are located. When a temperature decrease is detected below  26 ± 2°C [71], 
the TRPM8 effects the peripheral nerve endings that are cold specific and non-nociceptive (A delta 
fibres) by increasing concurrent flow resulting in cold perception [71, 72]. Menthol acts 
presynaptically where the TRPM8 channels congregate on somatic sensory neurons. While 
Menthol is a ligand for TRPM8, it is not specific to only the TRPM8 channel and will interact with 
other transient receptor protein (TRP) channels such as TRPA1 and TRPV3 [73]. These ion 
channels have been shown to induce different sensations in patients. They may elicit pain and 
inflammatory symptoms in some cases, while, in others, these proteins have been shown to 
contribute to pain analgesia [72, 74]. The analgesic effect of menthol may also be mediated by 
mechanisms independent of TRP channel proteins. Menthol can activate several pathways that all 
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contribute to reduced nociception. Menthol can activate GABAA-receptors, which could result in 
inhibition of nociception through central mechanisms [75, 76]. Menthol also affects voltage-gated 
sodium channels which inactivates the ability of sensory neurons to induce action potentials [77]. 
It was also found that menthol inhibits neuronal voltage-dependent Ca2+ channels [78, 79], 
nicotinic acetyl choline receptors, and serotonin-gated ion channels, all of which have been linked 
to pain messaging [80, 81].  
1.8 Menthol and Human Performance 
Menthol is a commonly used topical analgesic in gels which are meant to reduce DOMS 
post exercise through mechanisms previously stated. However, does this perceived reduction in 
muscle pain lead to any alterations in human performance? Few studies have investigated this 
using menthol.  Johar et al. [82]  assessed the use of menthol applied to the bicep brachii of 
untrained individuals and found that menthol did significantly reduce DOMS compared to ice 
application, Also, tetanic force was higher in the menthol group compared to the ice group. 
However voluntary force (MVC) did not follow this trend and was not significantly different 
between groups.  These results may be due to voluntary force requiring activation of higher order 
systems which have not been affected by the topical application of the menthol whereas tetanic 
force occurs at the muscle level where sensory afferent fibres may already have been inhibited by 
the analgesic allowing for a higher motor output. These results slightly differ from those of Topp 
et al. [83] as they saw an elevation in maximum voluntary wrist flexion and extension strength 
with the application of menthol compared to ice application to the lower arm. However, there was 
no difference between the menthol and placebo control group, suggesting that menthol had no 
effect on strength production and in fact ice reduced power in untrained individuals.  
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1.9 Corticospinal Tracts 
Voluntary movement is determined and controlled by both the corticobulbar and 
corticospinal tracts [84]. Both tracts originate at the motor cortex, however corticospinal fibres 
innervate the majority of the body through spinal motoneurones which travel to the limbs and core 
muscles. This tract is the most important for voluntary body movements such as single and multi-
jointed movements. In contrast, the role of corticobulbar fibre motor nuclei is focused on 
controlling facial muscles so it is less studied in human movement trials. Techniques have been 
developed to stimulate different portions of the corticospinal tract, allowing researchers to access 
changes in excitability throughout the tract and better understand the etiology of what has occurred. 
These techniques are essential as the corticospinal tract seems to be easily altered by many 
variables such as pain, fatigue, position and movement.  
 
2.0 Stimulation Techniques to Assess Corticospinal Excitability 
2.0.1 Transcranial Magnetic Stimulation (TMS) 
TMS elicits motor evoked potentials (MEP) recorded with EMG of the muscle. TMS is 
elicited over the motor cortex in the area of the motor homunculus associated with the muscle of 
interest. A variety of coils can be used depending on the experimental setup and the question to be 
answered. Using a generic circular coil is less focal and activates a large portion of the motor 
homunculus, whereas, a double coil figure eight set-up provides more focal stimulation.  Both of 
these coils have pros and cons. The generic circular coil is placed horizontally over the vertex with 
a wide spread area of activation so even if the placement of the coil is altered slightly, similar areas 
of the homunculus will be activated. This increases the reliability even in less trained researchers 
[85]. However, when testing for corticospinal excitability we assume that only the motor 
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homunculus is activated but with such an indirect form of stimulation, excitation occurs in other 
areas of the brain which has been proven to have an effect on corticospinal excitability [86]. This 
activation in other regions could bias the results, decreasing the validity and reliability. With the 
figure eight coil we see the exact opposite effect. Due to a precise stimulation region, measures 
must be taken so that the coil is positioned over the exact same position of the skull. To achieve 
this goal, researchers have derived a plethora of techniques. One example is to have the participant 
wear a swim cap with the area of stimulation marked off. However, even with this method there 
are limitations as there is no way to ensure the cap does not move or that it is placed on the head 
in the same position each day.  
TMS activates corticospinal neurones leading to the activation of motoneurones. By using 
epidural or single motor unit recordings,  Lazzaro et al. [87] and Amassian et al. [88] have shown 
that there are multiple components of the MEP. Short latency direct waves (D-waves) which are 
direct activation of these motoneurones by a single synapse, followed by longer latency indirect 
waves (I-waves) which require multiple synapses to reach the motoneurone. High intensity TMS 
is best used for eliciting a D wave and is caused by direct depolarization of the initial axon segment 
of the corticospinal neurone. I-waves will occur 1.5 ms after a D wave, showing evidence of 
synaptic discharge. I-waves are elicited along the tract when TMS intensity is put above motor 
threshold [89]. These elicited waves can be altered by many different factors such as: modulation 
of neurotransmission (i.e., acetylcholine, norepinephrine, and dopamine) [90], neurotransmitters 
(i.e., glutamate, GABA), interneurones contacted by corticospinal tract cells and activity-
dependent changes (i.e. voluntary contraction) [91]. MEP amplitude is affected by all these factors. 
However, MEP amplitude is not a result of cortical changes alone but changes at the spinal level 
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as well. Therefore, it can be hard to determine where the change in the corticospinal tract has 
occurred. Any alteration in MEP amplitude represents a change in the  neuromuscular system [92].  
Due to this ambiguity, it is important to be able to activate the corticospinal tract at a 
subcortical level which would allow for a better interpretation of responses evoked at the cortex 
[93-97].  
2.0.2 Transmastoid electrical stimulation (TMES) 
 
TMES elicits a cervicomedullary evoked potential (CMEP). The stimulation is delivered 
via adhesive electrodes fixed to the skin over the mastoid processes and current is passed between 
them, creating a single descending volley. In 1991, Ugawa, Rothwell [98] developed this method 
to stimulate the descending axons at a subcortical level in order to test spinal excitability (i.e. 
motoneurones). This single volley contrasts with that of TMS because TMS evokes multiple 
descending volleys that stimulates corticospinal motoneurones multiple times. The CMEP can be 
utilized as a measure of motoneurone excitability [99-101]. A fixed latency of the response shows 
activation of fast descending axons at the level of the pyramidal decussation at the 
cervicomedullary junction [102, 103]. The stimulation is made possible due to the bending of 
axons at the decussation, however stimulation at this site is found to be unpleasant. TMES is the 
most direct method of motoneurone measurement because the descending tracts are not subject to 
conventional presynaptic inhibition[104, 105]. CMEP however, can have some inconsistencies. If 
performed incorrectly, activation of peripheral nerve roots independently of spinal stimulation is 
commonly seen to contaminate CMEP responses. The accepted amount of root activation in CMEP 
responses exists as percentage of the amplitude of the response. Any activation of peripheral nerves 
could have an effect on the output that is proposed to be of spinal origin. This interference effects 
the reliability of the result and could decrease the internal validity of the experiment as there could 
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be different degree of peripheral activation based on placement of electrodes and anatomic 
variation of participants. Another issue with TMES is the painful shock needed to elicit the CMEP 
response. Since it is well known that afferent information has a large effect on corticospinal output, 
this activation of A-delta and C fibres from pain could hinder the reliability of the results.  
2.0.3 Brachial Plexus stimulation 
  To perform brachial plexus stimulation, Erb's point is electrically excited via adhesive Ag-
AgCl electrodes fixed to the skin over the supraclavicular fossa (cathode) and the acromion process 
(anode). Current pulses can be delivered as a singlet or doublet via a constant current stimulator. 
The electrical current is gradually increased until the muscle compound action potential (M-wave) 
of the biceps no longer increases (i.e. Mmax). A supramaximal stimulation current (i.e. 20% higher 
than that required to elicit Mmax) is often used as a reference for MEPs and CMEPs in testing 
procedures due to its consistent results. This process accurately accesses the peripheral excitability 
of the nervous system. The peripheral nerve being stimulated aswell as the neuromuscular junction 
and the muscle itself are not part of the central nervous system however they can alter peripheral 
excitability as well as overall motor output. [106, 107] Both MEP and CMEP amplitudes or areas 
are usually expressed as a percentage of Mmax to take into account the effect of muscle excitability 
on corticospinal excitability. Meaning it allows researchers to eliminate potential differences in 
excitability of the peripheral and better pinpoint where changes occurred along the corticospinal 
pathway. 
2.0.4 Electromyography 
All evoked potentials from TMS, TMES and M-wave responses are recorded and measured 
from muscle electromyography (EMG). Thus, EMG recording is the primary way corticospinal 
excitability is measured. Surface EMG recording electrodes are placed 2 cm apart (center to center) 
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over the mid-point of the muscle belly of the participant. A ground electrode is placed on a point 
on the body where there is no electrical activity such as the lateral epicondyle. In order to get as 
accurate results as possible, skin preparation is done for all electrodes, which includes shaving hair 
off the desired area followed by cleansing with an isopropyl alcohol swab. This allows for 
decreased skin resistance during recording. An inter-electrode impedance of < 5 kOhms is required 
prior to recording to ensure an adequate signal-to-noise ratio so that the results obtained are reliable 
and voided of the majority of false noise.  EMG signals, depending on intensity, are usually 
amplified and filtered to further the reliability of the results.  
2.1 The Effect of Pain on Corticospinal Excitability 
 The change in activity of group III and IV muscle afferents is thought to induce changes in 
excitability of motoneurones in the spinal cord, or even further up in the motor pathway, such as 
in the motor cortex (for review see [67]). Group III and IV afferents have been observed to affect 
motoneurone pools differently in flexors and extensors in cat experiments [108, 109]. When 
activating afferents involved in nociception through chemical gradient changes, Schomburg et al, 
found depolarization in motoneurones activating flexors, but in contrast, they found that the 
motoneurones activating extensors were hyperpolarized. 
This phenomenon of flexor excitation and extensor inhibition has been seen before in the 
literature when looking at the effect of other classes of afferent neurons. These afferents are 
referred to the flexor reflex afferents [110]. A study by Martin et al. was able to show this same 
non-uniform effect on motoneurones, previously found in cats, in humans  [111]. The researchers 
were able to find excitation and inhibition in flexor and extensor human motoneurone responses 
respectively, by directly stimulating the corticospinal tract while in the presence of increased 
activity of group III and IV muscle afferents, caused by ischemia from fatiguing contractions. It 
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could be speculated that this reflex occurs in attempt to protect the muscle from pain. In order to 
pull a limb from harm, it requires that the muscles in the limb be flexed. For this to occur 
seamlessly, the antagonist, or extensor muscle, must collectively relax. These time sensitive 
protective measures are usually found to originate spinally, to reduce the processing time that 
would be required from the motor cortex. With that being said, responses acquired from TMS of 
the motor cortex have been found to change in the presence of inputs occurring from these group 
III and IV muscle afferents. Whether the cortically derived responses actually increase or decrease 
has been disputed in the literature [112, 113]. However, the responses found in these studies were 
a product of afferents that were excited under different conditions, for example the first study 
which showed an increase in motor cortex response was found in the presence of hypertonic 
solution injection in a resting muscle. The second found a  decrease in motor output caused by 
painful injection of ascorbic acid in an active muscle. Therefore, the differences found in 
corticospinal excitability could have been due to the solution differences or the presence of a 
resting verses active muscle. The uncertainty could also be due to the idea that muscle responses 
do not only depend on the motor cortex, as either spinal or peripheral mechanisms may play a role. 
Thus, further study must be done to assess the effects of these afferents on corticospinal 
excitability.  
More recently, Martin and colleagues have explored how the input of group III and IV 
muscle afferents differentially effect the output of the motor cortex and motoneurone excitability. 
To differentiate between the two, they stimulated the motor nerves in the motor cortex using TMS 
and in the corticospinal tract using TMES. They found a strong feedback from the muscle afferents, 
which differed depending on what type of exercise was taking place. During fatiguing activity, 
there was an inhibitory effect of the group III/IV afferents, which contrasted with the results found 
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during strenuous, non-fatiguing exercise, where group III/IV mediated feedback facilitated 
motoneuronal excitability without changing excitability to the entire pathway. These results show 
an increase in spinal excitability with a decrease in supraspinal excitability in the presence of non-
fatiguing exercise. However, one could also interpret that the input of these afferents may play a 
differential role while fatiguing exercise is being performed [114]. This idea was supported further 
in a paper published by Sidhu and colleges [115] which investigated lower limb muscle afferent 
feedback on the excitability of the motor cortex and spinal motoneurone projections to knee 
extensors during fatiguing and non-fatiguing cycling by attenuating group III/IV muscle afferents 
using lumbar intrathecal fentanyl. They found during cycling induced leg fatigue activation of 
III/IV afferents decreased the amount of voluntary descending drive from the motor cortex, which 
lead to a decline in both flexor and extensor muscle activation. This also caused a depressed 
excitability of the corticospinal pathway, including the motor cortex and spinal motoneurones in 
the presence of muscle group III/IV afferent activity [116]. 
In the presence of non-fatiguing painful exercise, it seems reasonable to see a facilitation 
of spinal excitability and a decrease in supraspinal excitability. It has been proposed that painful 
phenomenon is causing a prevention of motor cortex output so that spinal protective mechanisms 
can take place without interruption [117]. In contrast, while undergoing fatiguing exercise the 
properties of the afferent feedback interaction must switch. The objective no longer becomes 
pulling away from danger, instead, the body has to try and protect itself from further injury by 
reducing motor output as a whole, so that the fatiguing exercise, which is causing hardship, will 
stop. However, the Sidhu paper found some contrasting results in the presence of non-fatiguing 
exercise as group III/IV muscle afferents facilitated motor cortical cells, while inhibiting spinal 
motoneurones [115]. It is important to note that this study did not induce pain through added 
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stimuli, but instead, they blocked afferent input through the use of an injectable epidural analgesic 
(fentanyl). As a result, the inconsistency between this paper and the other studies using hypertonic 
solutions to activate III/IV muscle afferents, could be due to the differential activation of 
nociceptive versus non-nociceptive subtypes within these groups [118]. The inhibitory effect of 
the group III/IV afferents through analgesic block was speculated to be modulated through 
presynaptic inhibition of Ia afferents [119]. Due to the differential nature of the experimental 
procedure, the idea of spinal reflex takeover (Inhibition of the motor cortex that may allow the 
spinal motor system to freely respond to noxious stimulation) in the presence of pain may still 
stand true.  
There is still little known about the physiological reason behind most of these interactive 
mechanisms, however, a study by Mercier et al. [117] attempted to determine if sensorimotor 
integration, the interaction of pain afferents and motor output, occurred via the process of short 
afferent inhibition (SAI) in the cortex (for more information on SAI see [86]).  Their results 
showed no significant difference in SAI between the pain and neutral conditions, indicating that 
the interaction between pain/sensory and motor pathways is not mediated by direct rapid pathways 
and must involve higher order cognitive areas [120]. 
2.2 The Effect of Topical Analgesic on Corticospinal Excitability 
When adding a topical analgesic such as menthol to the already complex interactions of 
pain on the nervous system, it can only be speculated what changes may occur. Menthol has been 
shown to cause a presynaptic release of calcium by activating a family of membrane proteins called 
transient receptor potential channel M8 (TRPM8). This channel is a sensory molecule expressed 
on some primary afferent neurons. TRPM8’s function is to aid nerve endings in the periphery by 
sensing cool temperatures [121]. By activating TRPM8 through the use of menthol or even 
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cooling, you activate a subpopulation of afferents that have these TRP receptors present. 
Activation stimulates a central synaptic release of glutamate (Glu), This glutamate is thought to 
bind to Group II or III mGluR receptors on the presynaptic muscle damage-activated nociceptive 
afferents or possibly postsynaptically on dorsal-horn neurons, which causes attenuation of pain 
sensation [122]. This attenuation would presumably nullify the effect of the A-delta/C-fibres on 
the nervous system causing less presynaptic inhibition and in turn increasing motor output even in 
the presence of nociceptive muscle damage.  
2.3 Conclusion 
In conclusion, there is little known about the effect of increased nociceptive input on 
corticospinal excitability, especially the effect of DOMS on corticospinal excitability. DOMS is 
muscle pain that arises 24-72 hours after exercise involving unfamiliar strenuous muscle loading. 
DOMS is commonly induced by eccentric muscle contractions and may signify exercise-induced 
muscle damage including impaired excitation-contraction coupling and injury to cytoskeletal 
proteins in the sarcomere. During DOMS, muscle pain is transmitted via A-delta and C-fibre 
afferents (group III/IV afferents) to the central nervous system (CNS). While it has been shown 
that muscle force production is significantly diminished in DOMS, there is limited evidence on 
the influence of DOMS on corticospinal excitability or inhibition. One way to reduce the negative 
effect of DOMS on motor output and perhaps alter any DOMS induced changes in corticospinal 
excitability is by applying a topical analgesic over the muscle(s) with DOMS. Topical analgesic is 
thought to blunt the transmission of nociceptive throughout the CNS and in turn may alter 
corticospinal excitability following the application of it to a muscle experiencing DOMS. 
However, to date no work has investigated how the application of topical analgesic interacts with 
DOMS to mediate corticospinal excitability.  
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3.1 Abstract 
The interactive effect of delayed onset muscle soreness (DOMS) and a topical analgesic 
on corticospinal excitability was investigated during two experiments. A total of Thirty-two 
participants completed either Experiments A (No DOMS, n=16) and B (DOMS, n=16). For each 
experiment participants were randomly assigned to two groups: 1) menthol-based topical analgesic 
gel (Topical Analgesic, n=8), or 2) placebo gel (Placebo, n=8) group. Prior to the application of 
gel (pre-gel), as well as 5, 15, 30, and 45 min post-gel, motor evoked potential (MEP) area, latency, 
and silent period, as well as cervicomedullary MEP (CMEP) and maximal compound motor unit 
action potential (Mmax) areas and latencies were measured. In addition, pressure-pain threshold 
(PPT) was measured pre-DOMS and at the same time points in Experiment B. In Experiment A, 
neither group showed a significant change for any outcome measure. In Experiment B, both groups 
exhibited a significant increase in PPT from pre-DOMS to pre-gel (Topical Analgesic, pre-DOMS 
= 7.03±2.48 kg, pre-gel = 3.12±1.26 kg, p<.001; Placebo, pre-DOMS = 5.77±2.35 kg, pre-gel = 
3.51 ± 1.58 kg, p< .05). Following the application of topical analgesic, but not placebo, there was 
a significant increase in PPT at 15, 30, and 45 min post-gel (3.70±1.69, 3.92 ± 1.67 and 4.33±1.65 
kg, p<.05), respectively compared to pre-gel (3.12±1.26 kg) and an increase in silent period at 
post-30 and 45 min (96.08±26.62 ms and 94.23±22.32 ms, p<.05) compared to pre-gel 
(85.67±19.65 ms). DOMS reduced MEP area (Experiment A = 0.222±0.169; Experiment B = 
0.097±0.057, p<.02), CMEP area (Experiment A = 0.186±0.148; Experiment B = 0.077±0.045; 
p<.05), and increased MEP silent period (Experiment A = 77.41±31.05 ms; Experiment B = 
100.85±32.29 ms; p<.05). These findings suggest that DOMS reduced corticospinal excitability; 
and following the administration of menthol-based topical analgesic there was a reduction in pain, 
which was accompanied by increased corticospinal inhibition.  
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3.2 Introduction 
Delayed onset muscle soreness (DOMS) is muscle pain induced through unfamiliar 
strenuous muscle loading arising 24-72 hours post exercise [30]. Muscles soreness has been shown 
to activate type III/IV muscle afferent fibres [123] which induces neuromuscular impairments, 
including altered joint kinematics, a loss in force perception [60], muscular strength [59], joint 
angle perception, MVC production [59, 61-64], a decrease in muscle activation and increased 
EMG to force ratios [65]. The excitability of the corticospinal tract, considered the most dominant 
descending tract for voluntary control of motor output, has been studied under various including 
experimentally induced muscle soreness through hypertonic saline injection [112] or non-fatiguing 
ischemic exercise [109]. There are few studies, however, that have assessed corticospinal 
excitability (CSE) in the presence of DOMS.  
One way to quantify CSE is via transcranial magnetic stimulation (TMS) and transmastoid 
electrical stimulation (TMES). TMS and TMES elicit motor evoked potentials (MEP) and a 
cervicomedullary MEPs (CMEP), respectively. By using both of these approaches one can assess 
if changes are of supraspinal or spinal origin along the corticospinal pathway. TMS activates 
corticospinal neurons leading to the activation of motoneurones. MEPs provide an idea of the 
excitability of the motor system at the time of the TMS pulse. The amplitude or area of MEPs 
produced by single-pulse TMS indicates the summation of excitatory and inhibitory inputs to the 
corticospinal pathway, allowing a measure of CSE to which both supraspinal and spinal 
excitability contribute [121]. In addition, the cortical silent period (CSP) is a period of dormancy 
in the rectified EMG trace immediately after a MEP, when TMS is delivered during a sustained 
tonic contraction of the target muscle contralateral to the motor cortex M1 [124, 125]. It has been 
suggested that the level of contraction and the size of the MEP do not impact CSP, while its 
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duration tends to increase linearly with TMS stimulus intensity [126, 127]. Duration of the CSP is 
thought to be influenced by both cortical and central mechanisms [124] In the cortex, γ-
aminobutyric acid (GABA)-ergic interneurons (i.e., GABAB receptors) appear to mediate the CSP 
[128, 129]. 
Activation of group III and IV muscle afferents has been shown to induce changes in the 
excitability of motoneurones both spinally and supraspinally (for review see [67]). In cat 
experiments, researchers have found these afferents differentially influence flexor and extensor 
motoneurone pools [106, 107]. These experiments activated III/IV muscle afferents involved in 
nociception by intra-arterial injections of potassium and bradykinin, and the researchers found 
depolarization in motoneurones leading to activation in flexors, by contrast, motoneurones 
activating extensors were hyperpolarized leading to inhibition. This phenomenon of flexor 
excitation and extensor inhibition has been seen before in the literature when looking at the effect 
of other classes of afferent neurons. These afferents are referred to the flexor reflex afferents [108]. 
A study by Martin et al. [109] was able to show the same non-uniform effect on motoneurones 
previously found in cats also occur in humans. The researchers were able to find excitation in 
flexor and inhibition in extensor motoneurone response, by directly stimulating the corticospinal 
tract through TMS and TMES in the presence of increased activity of group III and IV muscle 
afferents, caused by ischemia from fatiguing contractions. Martin et al. [112] also determined how 
group III and IV muscle afferents activation differentially affected the excitability of the motor 
cortex and spinal cord, respectively. To differentiate between the two, they stimulated the motor 
cortex using transcranial magnetic stimulation (TMS) and the corticospinal tract using 
transmastoid electrical stimulation (TMES). By using hypertonic saline injections to activate III/IV 
muscle afferents, they showed an increase in spinal excitability with a decrease in supraspinal 
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excitability without a change in MEP amplitude [112]. Sidhu and colleagues [113] investigated 
lower limb muscle afferent feedback on the excitability of the motor cortex and spinal 
motoneurone projections to knee extensors during fatiguing and non-fatiguing cycling by 
attenuating group III/IV muscle afferents using lumbar intrathecal fentanyl. They found during 
cycling induced leg fatigue activation of III/IV afferents decreased the amount of voluntary 
descending drive from the motor cortex, which lead to a decline in both flexor and extensor muscle 
activation. In a second study, they were able to show depressed excitability of the corticospinal 
pathway, including the motor cortex and spinal motoneurones to an upper limb muscle during 
fatiguing leg exercise in the presence of muscle group III/IV afferent activity [114]. 
In the presence of painful exercise, it seems reasonable to see a facilitation of spinal 
excitability and a decrease in supraspinal excitability. It has been proposed that painful 
phenomenon is causing a prevention of motor cortex input so that spinal protective mechanisms 
can take place without interruption [115]. Sidhu et al., [113] did find contrasting results to support 
this, in the presence of non-fatiguing exercise, group III/IV muscle afferents facilitated motor 
cortical cells, while inhibiting spinal motoneurones [113] but during exhausting exercise the motor 
cortex was inhibited and motoneurons were unaffected. It is important to note that this study did 
not induce pain through added stimuli, but instead, they blocked afferent input through the use of 
an injectable epidural analgesic (fentanyl). As a result, the inconsistencies between this paper and 
the other studies using hypertonic solutions to activate III/IV muscle afferents, could be due to the 
differential activation of nociceptive versus non-nociceptive subtypes within these groups [116]. 
A number of studies looking at single motor unit recordings in biceps showed that 
DOMS increased mean motor unit discharge rates and synchronization, while decreasing motor 
unit recruitment thresholds [125, 126]. In a study by Vansgaard et al., middle trapezius eccentric 
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muscle contraction-induced DOMS resulted in increased stimulus intensity needed to achieve 
baseline H-reflex amplitude, 24 hours post-exercise. This suggested diminished spinal excitability 
produced by presynaptic inhibition of Ia afferent fibres, the afferent arc of the H-wave, by group 
III/IV afferents [127]. So there is evidence of some spinal alteration involved in DOMS associated 
deficits. Despite the above research findings, there is limited evidence on the influence of DOMS 
on CSE or corticospinal inhibition. Likewise, it is unknown whether CNS effects of DOMS are 
restricted to changes at the spinal versus supraspinal level [128]. 
When adding topical analgesic such as menthol to the complex interplay between DOMS 
and motor output, it can only be speculated what changes may occur. Menthol acts on a subset of 
transient receptor proteins (TRPs) which are membrane proteins called transient receptor potential 
channel M8 (TRPM8) [119]. The activation of the afferent fibres through these receptors has been 
shown to cause a presynaptic release of calcium as well as a central synaptic release of glutamate. 
This glutamate is thought to bind to Group II or III mGluR receptors on the presynaptic muscle 
damage-activated nociceptive afferents or possibly post-synaptically on dorsal-horn neurons, 
which causes attenuation of pain sensation [120]. Thus, a topical analgesic (i.e. menthol) may 
nullify the effect of the group III/IV muscle afferents on the nervous system causing less 
presynaptic inhibition and in turn increasing motor output even in the presence of nociceptive 
muscle damage. 
 The purpose of this study was to assess the: 1) effect of DOMS on CSE and 2) interactive 
effect of DOMS and a topical analgesic gel on CSE. We hypothesized that DOMS would result in 
cortical inhibition and spinal facilitation which would be attenuated by the application of a topical 
anesthetic. 
 
 38 
 
3.3 Methods 
Participants 
 
Sixteen young healthy adult participants were recruited for Experiment A: No DOMS and 
16 young healthy adult male participants were recruited for Experiment B: DOMS. Five 
participants from Experiment A also performed Experiment B (see Table 1 for participant 
demographics). All participants were recreationally active (~10 hours of activity/week). Prior to 
testing, all participants completed the magnetic stimulation safety checklist (Rossi, Hallett, 
Rossini, & Pascual-Leone, 2011) and Physical Activity Readiness Questionnaire (Canadian 
Society for Exercise Physiology (CSEP), 2002). Additionally, participants were instructed to 
refrain from heavy exercise 24 hours before testing and to follow the Canadian Society for Exercise 
Physiology preliminary instructions (i.e., no eating for 2 hours, drinking caffeine for 2 hours, 
smoking for 2 hours, or drinking alcohol for 6 hours) (CSEP, 2013) prior to the start of testing. 
Before participating in the study, each participant was initially briefed verbally and in writing as 
to the risks of the research and was given the opportunity to provide written informed consent, in 
compliance with the Declaration of Helsinki and the university’s institutional ethics review board 
regulations. The University’s Interdisciplinary Committee on Ethics in Human Research approved 
the study (#20171278-HK), which was in accordance with the Tri-Council guidelines in Canada 
with full disclosure of potential risks to participants.  
DOMS Protocol 
 
In Experiment B only, participants performed an eccentric elbow flexor contraction 
protocol to induce DOMS. For all participants, this protocol was completed using a HUMAC 
NORM dynamometer (CSMi Medical Solutions, Stoughton, MA, USA). The elbow of the 
dominant arm was aligned with the rotational axis of the dynamometer. Excess movement was 
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reduced by using shoulder weights and chest straps. Participants were seated upright with their 
back supported at a 90º angle and were instructed to complete a comfortable range of motion 
(~110º degrees of rotation, on average). The desired range of motion was then divided by 5, to 
establish participants’ required degrees per second for the eccentric contraction used during the 
DOMS protocol. The protocol began with 1 warmup set which consisted of eccentric contractions 
that were perceived by the participant to be approximately 50% maximum eccentric torque output. 
Once the warmup set was completed, participants performed the DOMS protocol which consisted 
of only eccentric contractions for 5 sets of 10 repetitions that were 5 seconds each in duration. 
Participants were given 90 seconds of rest between each set. Following each eccentric contraction, 
participants were told to apply no force as the dynamometer passively brought the arm back to full 
flexion. Participants were instructed to maximally contract for each eccentric contraction.  
Elbow Flexor Force 
 
Participants were seated in a custom-built chair (Technical Services, Memorial University 
of Newfoundland, St. John’s, NL, Canada) in an upright position, with the chest and head strapped 
in place to minimize movement, and the hips and knees flexed at 90º. The shoulder was placed at 
0º and the elbow was flexed at 90º. At the 0º position, both arms were slightly abducted and rested 
on a padded support. The forearm was held horizontal, positioned midway between neutral and 
supinated positions, and placed in a custom-made orthosis that was connected to a load cell 
(Omegadyne Inc., Sunbury, OH, USA). The load cell detected force output, which was amplified 
× 1000 (CED 1902, Cambridge Electronic Design Ltd., Cambridge, UK) and displayed on a 
computer screen. Data were sampled at 2000 Hz. Participants were instructed to maintain an 
upright position with their head in a neutral position during contractions of the elbow flexors. 
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Verbal encouragement and visual feedback (Signal 4.0 software, Cambridge Electronic Design 
Ltd., Cambridge, UK) were given to all participants during elbow flexor contractions.  
Electromyography (EMG) 
 
Participants’ EMG activity was recorded using bipolar surface EMG recording electrodes 
(Meditrace Ag-AgCl pellet electrodes, disc-shaped 10 mm diameter, Graphic Controls Ltd., 
Buffalo, NY, USA) from the biceps brachii muscle of the dominant arm. Electrodes were placed 
2 cm apart (center to center) over the midpoint of the muscle belly of each participant’s dominant 
biceps brachii muscle. A ground electrode was placed over the lateral epicondyle of the ipsilateral 
knee. Skin preparation for all recording electrodes included shaving the skin to remove excess hair, 
lightly abrading the skin surface with fine-grit sandpaper to remove excess dry epithelial cells, and 
cleaning the skin with a 70% isopropyl alcohol swab to eliminate dry epithelial cells. An inter-
electrode impedance of < 5 kΩ was obtained prior to recording to ensure an adequate signal-to-
noise ratio. All EMG signals were amplified (× 1000) (CED 1902, Cambridge Electronic Design 
Ltd., Cambridge, UK) and filtered using a 3-pole Butterworth filter with cut-off frequencies of 10-
1000 Hz. All signals were analog-to-digital converted at a sampling rate of 5000 Hz using a CED 
1401 interface (Cambridge Electronic Design Ltd., Cambridge, UK).  
Stimulation Conditions  
 
Transcranial magnetic stimulation (TMS) 
 
 TMS-elicited motor evoked potentials (MEPs) were used to measure corticospinal 
excitability (CSE) in all participants. TMS was delivered using a circular coil (13 cm outside 
diameter, Magstim Company Ltd., Carmarthenshire, UK) and Magstim 2002 magnetic stimulator 
(maximal output 2.0 T, Magstim Company Ltd., Carmarthenshire, UK). The stimulating coil was 
positioned directly over the vertex of participants’ head to induce MEPs in the relaxed and active 
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(5% maximal voluntary contraction (MVC)) biceps brachii muscle [93]. The vertex was located 
by marking the measured halfway points between the nasion and inion and the tragus to tragus. 
The intersection of these two points was defined as the vertex and was clearly marked with a felt-
tipped permanent marker. Electrical currents flowed in an anticlockwise direction through the 
circular coil. The coil was placed horizontally over the vertex so that the direction of the current 
flow in the coil preferentially activated the right or left primary motor cortex (“A” side up for right 
side, “B” side up for left side), for the elicitation of current in of the dominant biceps brachii motor 
cortical representation [129]. Stimulation intensity was set to elicit a threshold MEP (active motor 
threshold (AMT)), with the size needing to be discernible from the background EMG at 5% of 
MVC in 50% of the trials (i.e., 4 out of 8 trials) in the biceps brachii muscle [130]. Stimulator 
output was then increased to 20% above AMT for the remainder of the experiment (Experiment 
A: No DOMS: M ± SD stimulation intensity = 46 ± 6 %MSO, range = 36-58 %MSO; Experiment 
B: DOMS: M ± SD stimulation intensity = 57 ± 8 %MSO, range = 42-74 %MSO) [93]. At each 
time-point of interest (see Experimental Protocols section below), 10 MEP trials were measured 
at 20% above AMT. 
Transmastoid electrical stimulation (TMES) 
 
 TMES was applied via surface electrodes (Meditrace Ag-AgCl pellet electrodes, disc-
shaped 10 mm diameter, Graphic Controls Ltd., Buffalo, NY, USA) placed over the mastoid 
processes with current passed between the electrodes by a constant-current electrical stimulator 
(square wave pulse, 200 µs duration; model DS7AH, Digitimer Ltd, Welwyn Garden City, UK). 
Stimulation intensity was adjusted to prevent ventral root activation by closely monitoring 
cervicomedullary evoked potential (CMEP) responses for any decrease in onset latency (~2 ms), 
which indicates cervical ventral root activation [93]. Stimulation intensity was adjusted to elicit a 
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CMEP response that matched the size of the average MEP amplitude (recorded at 20% above 
threshold) during 5% of MVC (Experiment A: No DOMS: M ± SD stimulation intensity = 121.5 
± 22.2 mA, range = 90.0-155.0; Experiment B: M ± SD stimulation intensity = 129.8 ± 25.5 mA, 
range = 92.0-176.0 mA). At each time-point of interest (see Experimental Protocols section 
below), eight CMEP trials were measured at 20% above CMEP threshold. 
Brachial plexus stimulation  
 
 Stimulation of the brachial plexus was used to measure participants’ maximal compound 
motor unit action potential (Mmax). Erb’s point was electrically stimulated via a cathode 
(Meditrace Ag-AgCl pellet electrode, disc-shaped 10 mm diameter, Graphic Controls Ltd., 
Buffalo, NY, USA) positioned on the skin overlying the supraclavicular fossa and an anode 
electrode (Meditrace Ag-AgCl pellet electrodes, disc-shaped 10 mm diameter, Graphic Controls 
Ltd., Buffalo, NY, USA) placed over the acromion process. Current pulses were delivered as a 
singlet using a constant-current electrical stimulator (square wave pulse, 200 μs duration; model 
DS7AH, Digitimer Ltd, Welwyn Garden City, UK). The electrical current was gradually increased 
until Mmax of the biceps brachii muscle was reached at rest. The maximal stimulation intensity 
used to determine Mmax during rest was then used throughout the rest of the experiment 
(Experiment A: No DOMS: M ± SD stimulation intensity = 112.1 ± 124.3 mA, range = 80.0-165.0 
mA; Experiment B: M ± SD stimulation intensity = 139.1 ± 45.4 mA, range = 75.0-255.0 mA). At 
each time-point of interest (see Experimental Protocols section below), three Mmax trials were 
measured at the stimulator intensity used to arrive at Mmax.  
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Pressure-pain threshold (PPT) 
In Experiment B only, PPT was quantified for each participant’s dominant biceps brachii 
muscle during each session via a pressure-pain algometer. A mark was placed on the participant’s 
biceps brachii muscle at the mid-belly, 9 cm above the antecubital space on the first day of testing 
to ensure measurements were reliable between testing sessions [131]. The algometer (Lafayette 
Manual Muscle Test System™, Model 01163, Lafayette Instrument Company, IN, USA) was a 
handheld muscle tester with a pressure range of 0-136.1 kg, comprised of a padded disc with a 
surface area of 1.7 cm2, attached to a microprocessor-control unit that measured peak pressure 
(kg). The unit had a digital readout for peak-applied pressure and provided a built-in calibration 
routine that verified a valid calibration. To determine PPT, the researcher would apply the 
algometer at a gradual force rate of 50-60 kPa/s to the marked spot on the participant’s biceps 
brachii muscle until the participant verbally informed the researcher when the sensation of pressure 
became painful [132]. At the point of pain, the pressure-pain algometer was removed and the PPT 
value was recorded. PPT values were obtained every 30 seconds over the tender spot using the 
pressure-pain algometer at each time-point of interest (see Experimental Protocols section below).  
Experimental Protocols 
For Experiment A and Experiment B participants were randomly allocated to one of two 
groups: 1) topical analgesic gel (Topical Analgesic, n = 8 for each experiment); or 2) placebo gel 
(Placebo, n = 8 for each experiment) (Table 1). Throughout the experiments, both the experimenter 
and participant were blinded to the group allocation and gel type of each participant. Each 
participant was assigned an unmarked tube of gel that contained only a randomization code. The 
identity of the code was unknown to the experimenter who interacted with the participants during 
the application of gel. For Experiment A, all participants were required to attend one testing session 
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for approximately 1.5-2 hours. For Experiment B, all participants were required to attend two 
testing sessions, with the first session lasting approximately 45 minutes and the second session 
lasting approximately 1.5-2 hours. In both experiments either 2 mL of menthol-based topical 
analgesic gel (Biofreeze®, containing 3.5% menthol; Topical Analgesic) or 2 mL of placebo gel 
(containing the same ingredients as Biofreeze®, except menthol; Placebo), were applied topically 
over the belly of the dominant biceps brachii muscle. During Experiment A this occurred in the 
single testing session; for Experiment B, gel was applied during the second testing session. The 
gel was gently applied by an experimenter, and the mode of application for the gels did not involve 
substantial force, pressure, or rubbing. The same experimenter applied the gel for each participant 
and the method of application did not differ across groups. The dose of gel (2 mL) was based upon 
the estimate that the average skin surface area over the biceps brachii was approximately 400 cm2, 
as well as the recommended dosage of Biofreeze® of 1 mL per 200 cm2 of skin surface area [82, 
133]  
Experiment A protocol 
 
During the experimental session participants were familiarized with the different 
stimulations they would receive (i.e., TMS, TMES, brachial plexus stimulation; see Stimulation 
conditions section). Participants were positioned to perform an elbow flexion MVC throughout all 
stimulation procedures (see Elbow Flexor Force section). Participants then completed two elbow 
flexors MVCs, which were required to have force measurements (N) within 5% of one another to 
ensure maximal force output; if not, a third MVC was performed. The MVCs were proceeded by 
a 10-minute rest period where the participants were prepped for EMG and stimulation conditions. 
Following 10 minutes of rest the stimulation intensities were set. Participants’ CSE measurements 
of the biceps brachii muscle (i.e., MEP, CMEP, Mmax) were taken pre-, as well as 5, 15, 30, and 
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45 minutes post-application of the gel. All stimulations were performed during a biceps brachii of 
the dominant upper-limb at 5% MVC. Biceps brachii contractions lasted for 80 seconds, to allow 
for the randomized recording of 10 MEPs, eight CMEPs, and three Mmax trials. All MEP and 
CMEP stimulations occurred at a frequency of 0.25 Hz; Mmax stimulations were delivered 2 
seconds randomly after a MEP recording. (See Figure 1a for experimental set up) 
Experiment B protocol 
 
During experimental session one, participants were familiarized with the different 
stimulations they would receive. Then PPT was measured (see Pressure-pain threshold (PPT) 
section). Following these measurements, the participants completed the DOMS protocol (see 
DOMS Protocol section). Participants were then instructed to come back to the laboratory 48 hours 
later to complete experimental session two. In experimental session two, participants completed 
the exact same stimulation protocol as in Experiment A (see Experiment A protocol section). In 
addition to the pre-DOMS measurement, PPT was recorded prior to, as well as 5, 15, 30, and 45 
minutes following the application of the gel, which took place after the CSE measurements at each 
time point. (See Figure 1b for experimental set up) 
Data Analysis 
 
 During the DOMS protocol, torque was measured for each repetition and peak torque was 
extracted for each set (see DOMS Protocol above). For measures of CSE (i.e., MEP, CMEP, 
Mmax), area was measured between cursors set from the initial EMG deﬂection from baseline to 
the second crossing of the horizontal axis [134]. MEP and CMEP areas were extracted in millivolts 
× seconds (mV·s) units. The average of all respective MEP (n = 10) and CMEP (n = 8) areas were 
normalized to the recorded Mmax (n = 3) area values within the same time point (i.e., pre-gel, 
post-5 min, post-15 min, post-30 min, post-45 min); MEP area and CMEP area data reported in 
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the results section were expressed as ratios relative to Mmax area. Mmax is a stable measure of 
muscle activity during maximal muscle fibre recruitment [135] and was thus used as the reference 
to normalize measures of CSE [136]. For MEPs, the duration of the silent period was considered 
as the time lapse between MEP offset and the re-onset of muscle activity [137, 138]. Silent period 
was extracted in ms units and all 10 MEP trials were averaged. Additionally, the latency of MEPs, 
CMEPs, and Mmax measurements were also extracted in ms as the duration from the stimulus 
artifact to the initial deflection from baseline and were averaged across the total number of 
stimulation trials (MEP, n = 10; CMEP, n = 8, Mmax, n = 3). All torque and CSE data were 
measured offline using Signal 4.0 software (Cambridge Electronic Design Ltd., Cambridge, UK), 
and averages and ratios were calculated using Office Excel 2016 (Microsoft Corporation, 
Redmond, WA, USA). 
 Demographic information used to characterize the study sample in both experiments 
included age (yr), body mass (kg), and height (cm) (Table 1). In Experiment A, sex was also 
recorded because the sample was comprised of both females and males, whereas the sample in 
Experiment B consisted of males only. In Experiment B, decrease in peak torque (%) from the first 
to the last set of the DOMS protocol was reported. Percent-changes in peak torque were calculated 
by extracting the difference between peak torque values (N·m) from the first and final sets of the 
DOMS protocol, relative to the peak torque value of the first set. This value was used to quantify 
the resistance employed in the DOMS protocol across groups. Neurophysiological outcome 
measures (i.e., CSE) considered in both experiments included MEP area/Mmax area ratio, MEP 
latency (ms) and silent period (ms), CMEP area/Mmax area, CMEP latency (ms), Mmax area 
(mV·s), and Mmax latency (ms). PPT (kg) was also reported in Experiment B.  
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Prior to statistical analyses all data underwent quality control checks for missing datapoints 
and outliers. There were no missing data points in Experiment A. In Experiment B, PPT data were 
absent for one participant (P08) at all time-points (pre-DOMS, pre-gel; 5, 15, 30, and 45 min post-
gel) due to an equipment (i.e., pressure-pain algometer) malfunction. Two additional participants 
in Experiment B (P04, P07) did not have pre-DOMS PPT data for the same reason. These missing 
data points were inputed by determining the series average for the entire sample of Experiment B 
(including the Topical Analgesic and Placebo groups) at their respective time-points using the 
Missing Values Analysis and Transform functions in SPSS (V25.0, IBM Corporation, Armonk, 
NY, USA) (Gamst, Meyers, & Guarino, 2008). Outliers were considered data points that exceeded 
the sample mean of either respective experiment by ± three standard deviations (SD) (Portney & 
Watkins, 2009). In Experiment A raw data, one MEP area (0.1%), two CMEP latency (0.3%), and 
one Mmax latency (0.4%) trials were deemed outliers and were omitted. For Experiment B no 
outlier values were identified. Outlier analysis was performed using Microsoft Office Excel 2016 
(Redmond, WA, USA).  
Statistical Analysis 
 
Statistical analyses were completed using SPSS. Assumptions of normality (Shapiro-Wilk 
test), sphericity (Mauchley’s test), and homogeneity of variances (Levene’s test) were tested for 
all outcome measures, where appropriate. All data were deemed normally distributed. In the event 
of a violation of the assumption of sphericity, p-values were adjusted using the Greenhouse-
Geisser correction. If the assumption of homogeneity of variances was violated, p-values were 
adjusted (equal variances not assumed). These instances are indicated in the text below (see Results 
section). 
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Pre-gel values of all outcome measures and demographics were compared across groups 
using independent-samples t-tests, to ensure groups were well-matched at baseline. In Experiment 
A, the proportions of female and male participants in each group were compared using the Pearson 
χ2 test. For Experiment B, pre-DOMS and pre-gel values of PPT were compared across groups 
(Topical Analgesic, Placebo) using independent-samples t-tests to ensure matching at the study 
outset, as well as following the DOMS protocol, respectively. To establish that the DOMS protocol 
induced DOMS in both participant groups (Topical Analgesic, Placebo), pre-DOMS and pre-gel 
PPT values were compared within each respective group using paired-samples t-tests. To examine 
the effect of topical analgesic on CSE measures (Experiment A, Experiment B) and PPT 
(Experiment B), one-way repeated-measures analyses of variance (rmANOVAs) (Factor = TIME 
[pre-gel, and 5, 15, 30, and 45 min post-gel]) were performed on all outcome measures within each 
group (Topical Analgesic, Placebo) [139]. Any significant main effect of TIME was explored 
using paired-samples t-tests and Fisher’s Least Significant Difference adjustment.  
Finally, across Experiment A versus Experiment B, grand means of baseline data (with 
topical analgesic and placebo groups pooled) were compared to examine whether DOMS had a 
statistically significant effect on measures of CSE. To ensure the experimental samples were 
matched at baseline, participants’ age, height, and body mass were compared with independent-
samples t-tests; proportions of female and male participants were compared using the Pearson χ2 
test. Additionally, to determine whether participants’ sex influenced baseline statistical 
comparisons across experiments, analyses of covariance (ANCOVAs) were performed on all CSE 
data using the fixed factor EXPERIMENT (No DOMS, DOMS) and the covariate SEX (Female, 
Male). For main statistical tests, statistical significance was set at a level of p < .05. Subsequently, 
raw data are reported as mean (M) ± SD in the text and tables. In figures, data are expressed as 
 49 
ratios relative to pre-gel values (post-5 min/pre-gel, post-15 min/pre-gel, post-30 min/pre-gel, 
post-45 min/pre-gel), and are reported as M ± standard error of the mean (SEM = SD/√n). 
3.4 Results 
Experiment A: No DOMS 
Baseline data  
Between-group comparisons of baseline demographics and outcome measures can be 
found in Table 1 (demographics) and Table 2 (outcome measures), respectively. Across groups, 
there were no significant differences in demographics (age, mass, height, sex), indicating that 
groups were well-matched (age, mass, height, t(14) ≤ |0.348|, p ≥ .545; sex, χ2(1) = 1.000, p = .317). 
For baseline CSE measures, groups were not significantly different at baseline (t(14) ≤ |1.470|, p ≥ 
.121). 
Motor evoked potential (MEP) 
See Figure 2A, 2C, and Table 2 for MEP area/Mmax area ratios and MEP latencies and 
silent periods data. There was no significant main effect of TIME for either the topical analgesic 
(F(4, 28) = 0.795, p = .538; F(4, 28) = 0.942, p = .454; F(4, 28) = 0.534, p = .712) or placebo (F(4, 28) = 
1.068, p = .391; F(4, 28) = 2.345, p = .079; F(4, 28) = 1.328, p = .284) groups on MEP area/Mmax 
area ratios (Figure 1A), MEP latencies (Table 2), or silent periods (Figure 1C), respectively. 
 Cervicomedullary evoked potential (CMEP) 
See Figure 3A and Table 2 for CMEP area/Mmax area ratios and CMEP latencies data. 
There was no significant main effect of TIME for either the topical analgesic (F(4, 28) = 2.156, p = 
.100; F(4, 28) = 0.990, p = .429) or placebo (F(4, 28) = 1.358, p = .287; F(4, 28) = 0.821, p = .424) groups 
on CMEP area/Mmax area ratios (Figure 3A) or CMEP latencies (Table 2), respectively. 
Maximal compound motor unit action potential (Mmax) 
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See Table 2 for Mmax areas and latencies data. There was no significant main effect of 
TIME for either the topical analgesic (F(4, 28) = 0.756, p = .562; F(4, 28) = 1.067, p = .339) or placebo 
(F(4, 28) = 1.068, p = .391; F(4, 28) = 0.537, p = .535) groups on Mmax areas or latencies, respectively 
(Table 2). 
Experiment B: DOMS 
Baseline data 
Between-group comparisons of baseline demographics and outcome measures can be 
found in Table 1 (demographics) and Table 3 (outcome measures), respectively. Across groups, 
there were no significant differences in demographics (age, mass, height) or DOMS protocol 
resistance (% decrease in peak torque), indicating that groups were well-matched (t(14) ≤ |0.208|, p 
≥ .267). In terms of baseline outcome measures, groups were not significantly different at baseline 
(t(14) ≤ |0.064|, p ≥ .184); however, for silent period and CMEP area/Mmax area, there were trends 
towards significance (silent period, t(14) = -2.078, p = .057; CMEP area/Mmax area, t(14) = -2.039, 
p = .061) whereby these values tended to be greater in the placebo group (silent period = 116.03 ± 
36.36 ms; CMEP area/Mmax area = 0.098 ± 0.044) versus the topical analgesic group (silent period 
= 85.67 ± 19.65 ms; CMEP area/Mmax area = 0.056 ± 0.039). In terms of PPT, groups were not 
significantly different either prior to the commencement of the DOMS protocol (pre-DOMS, t(14) 
= 1.042, p = .315) or following the DOMS protocol (pre-gel, t(14) = 0.927, p = .370). However, for 
both groups there was a significant decrease in PPT following the inducement of DOMS (topical 
analgesic, pre-DOMS = 7.03 ± 2.48 kg, pre-gel = 3.12 ± 1.26 kg, t(7) = -8.470, p = .000063; placebo, 
pre-DOMS = 5.77 ± 2.35 kg, pre-gel = 3.51 ± 1.58 kg, t(7) = -4.013; p = .005). 
Motor evoked potential (MEP) 
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See Figure 2B, 2D, and Table 3 for MEP area/Mmax area ratios and MEP latencies and 
silent periods data. There was no significant main effect of TIME for the topical analgesic (F(4, 28) 
= 1.403, p = .276; F(4, 28) = 0.696, p = .601) group or the placebo (F(4, 28) = 1.1594, p = .204; F(4, 28) 
= 2.124, p = .104) group on MEP area/Mmax area ratios (Figure 2B), or MEP latencies (Table 3), 
respectively. 
 There was, however, a significant main effect of TIME for the topical analgesic group (F(4, 
28) = 3.194, p = .028) on silent periods (Figure 2D). Post hoc analyses showed that, compared to 
pre-gel values (85.67 ± 19.65 ms), there was a non-significant trend towards an increase in silent 
period at 5 min (93.20 ± 28.14 ms, t(7) = -2.005, p = .085), which returned to near-baseline at 15 
min (83.57 ± 16.41 ms, t(7) = 0.453, p = .665) post-gel application. However, at 30 min (96.08 ± 
26.62 ms, t(7) = -2.430, p = .045) and 45 min (94.23 ± 22.32 ms, t(7) = -2.726, p = .029) post-gel 
application, there was a significant increase in silent period compared to pre-gel (Figure 2D, Table 
3). There was no such main effect for TIME on silent period for the placebo group (F(4, 28) = 0.655, 
p = .497) (Figure 2D). 
 Cervicomedullary evoked potential (CMEP) 
See Figure 3B and Table 3 for CMEP area/Mmax area ratios and CMEP latencies data. 
There was no significant main effect of TIME for either the topical analgesic (F(4, 28) = 2.156, p = 
.100; F(4, 28) = 0.629, p = .646) or placebo (F(4, 28) = 0.761, p = .560; F(4, 28) = 0.559, p = .563) groups 
on CMEP area/Mmax area ratios (Figure 3B) or CMEP latencies (Table 3), respectively. 
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 Maximal compound motor unit action potential (Mmax) 
See Table 3 for Mmax areas and latencies data. There was no significant main effect of 
TIME for either the topical analgesic (F(4, 28) = 2.252, p = .089; F(4, 28) = 0.696, p = .601) or placebo 
(F(4, 28) = 0.495, p = .740; F(4, 28) = 0.917, p = .393) groups on Mmax areas or latencies, respectively 
(Table 3). 
Pressure-pain threshold (PPT) 
See Figure 4 and Table 3 for PPT data. There was a significant main effect of TIME for 
the topical analgesic group (F(4, 28) = 8.9681.358, p = .000086). Post hoc analyses showed PPT 
values significantly increased at 15 (3.70 ± 1.69 kg, t(7) = -2.619, p = .034), 30 (3.92 ± 1.67 kg, t(7) 
= -3.987, p = .005), and 45 min (4.33 ± 1.65 kg, t(7) = -4,566, p = .003) post-gel application 
compared to pre-gel (3.12 ± 1.26 kg) (Figure 3). A significant main effect of TIME was not 
observed for PPT values (F(4, 28) = 1.802, p = .156) in the placebo group (Figure 3).  
Comparison between Experiment A: No DOMS and Experiment B: DOMS 
Results from baseline comparisons across experiments can be found in Table 1 
(demographics), Table 4 (outcome measures), and Figure 5 (outcome measures). In terms of 
baseline demographic characteristics, participants in Experiment B: DOMS were significantly 
older (Experiment A, age = 23 ± 1.1 yr; Experiment B, age = 26 ± 5.1 yr; t(30) = -2.277, p = .037), 
taller (Experiment A, height = 174.2 ± 8.2 cm; Experiment B, height = 179.8 ± 6.1 cm; t(30) = -
2.213, p = .035), and more massive (Experiment A, mass = 71.9 ± 9.1 kg; Experiment B, mass = 
81.9 ± 9.1 kg; t(30) = -3.108, p = .004) than participants from Experiment A: No DOMS (Table 1). 
Regarding distribution of participants’ sex across samples there was a significantly greater 
proportion of females in Experiment A: No DOMS (n = 8) versus Experiment B: DOMS (n = 0; 
χ2(1) = 10.667, p = .001) (Table 1).  
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With reference to baseline (pre-gel) outcome measures, participants in Experiment B: 
DOMS demonstrated significantly smaller values of MEP area/Mmax area (Experiment A, 0.222 
± 0.169; Experiment A, 0.097 ± 0.057; t(30) = 2.821, p = .011) (Figure 5A) and CMEP area/Mmax 
area (Experiment A, 0.186 ± 0.148; Experiment B, 0.077 ± 0.045; t(30) = 2.814, p = .012) (Figure 
5B), as well as a significantly longer silent period (Experiment A, 77.41 ± 31.05 ms; Experiment 
B, 100.85 ± 32.29 ms; t(30) = -2.093, p = .045) (Figure 5C), compared to those in Experiment A: 
No DOMS (Table 4). Mmax area exhibited a nonsignificant trend towards a greater value in 
Experiment B: DOMS versus Experiment A: No DOMS (t(30) = -1.733, p = .093) (Table 4). Neither 
MEP latency, CMEP latency, nor Mmax latency showed a statistically significant difference across 
experiments at baseline (t(30) ≤ |1.697|, p ≥ .100) (Table 4). ANCOVA results revealed that the 
covariate SEX was not statistically significant in any analyses of outcome measures (F(2, 29) ≤ 
2.253, p ≥ .144), suggesting that the uneven distribution of females and males across experiments 
did not influence differences in outcomes pre-gel. 
3.5 Discussion  
This study determined the effect of delayed onset muscle soreness and the application of a 
menthol-based topical analgesic gel (Biofreeze®) on indices of corticospinal excitability (MEP, 
CMEP), inhibition (silent period), peripheral motor nerve excitability (Mmax), and pressure-pain 
threshold in the dominant biceps brachii muscle 48 hours post eccentric exercise. By comparing 
baseline data between two experiments (DOMS and No DOMS) we show that the DOMS induced 
activation of III/IV muscle afferents inhibited and/or dis-facilitated supraspinal and spinal 
excitability as well as increased inhibition in motor output. Following the application of an 
analgesic gel in the presence of DOMS there was a significant increase in the cortical silent period 
at the 30 and 45 minute time points. These findings were not observed either in persons with 
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DOMS for whom placebo gel was applied or in participants in whom DOMS was not induced. 
Furthermore, the application of the topical analgesic gel also altered pain caused by DOMS since 
we found a significant reduction in perceived pain at the 15,30 and 45-minute time points, a finding 
that did not occur in the placebo group.  
DOMS causes inhibition of the corticospinal pathway to the bicep brachii during  
active contraction.  
DOMS has been used as an experimental model of acute muscle pain (Lau et al., 2015), 
and represents exercise-induced muscle damage including impaired excitation-contraction 
coupling and injury to cytoskeletal proteins in the sarcomere [140, 141]. DOMS is muscle pain 
likely brought on by the generation of inflammatory substances such as bradykinin, potassium, 
serotonin, histamine, hydrogen ions, and prostaglandins, and transmitted via A-delta and C-fibre 
afferents (group III/IV afferents) to the CNS [141]. The significant decrease in MEP/Mmax area 
as well as CMEP/Mmax area represents an inhibition of the motor pathway at the supraspinal and 
spinal regions in the presence of DOMS. A study by Le Pera, et al., [110] showed similar results 
with a reduction in MEP amplitude as well as H-reflex amplitude, indicating reduction in both 
CSE and spinal excitability, in the presence of injected hypertonic saline into the abductor digiti 
minimi (ADM) muscle. Additional work by the same group showed that DOMS elicited by 
eccentric middle trapezius contraction required an increased stimulus intensity to reach the 
baseline H-reflex amplitude 24 hours post-exercise, suggesting a reduction in spinal excitability. 
It was postulated that group III/IV afferent activation by DOMS resulted in presynaptic inhibition 
of Ia afferent reflex fibre inputs to spinal motoneurones [127]. However, these results contrast 
other studies that also assessed both CSE and spinal excitability in flexor muscles, in which the 
presence of type III and IV afferent activation, caused a facilitation in excitability of spinal 
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motoneurones and an inhibition of cortical cells [109, 112]. It could be speculated that this 
facilitation occurs in attempt to protect the muscle from pain. In order to protect a limb from 
potential injury, generally the muscles in the limb are rapidly flexed, and for this to occur quickly, 
the antagonist, or extensor muscle, must concomitantly relax. These time sensitive protective 
measures are usually found to originate spinally, possibly to reduce the processing time that would 
be required from the motor cortex. However, responses acquired from TMS of the motor cortex 
have also been found to be altered with the presence of activation of these group III and IV muscle 
afferents. With activation, whether the motor output is increased or decreased has been disputed 
in the literature [110, 111]. However, the responses found in these studies were a product of 
afferent stimulation under different conditions, with the increase in motor cortex response 
occurring after hypertonic solution injection in a resting muscle and the decrease associated with 
painful injection of ascorbic acid in an active muscle. Therefore, the differences found in CSE 
could have been due to the solution differences or the presence of a resting versus active muscle 
or potentially a combination of both. The uncertainty could also be due to the idea that muscle 
responses do not only depend on the motor cortex, as either spinal or peripheral mechanisms may 
play a role.  
Other studies have found no change in any measures of CSE attributable to activation of 
these afferent fibres [131]. However, these studies activated type III/IV afferents through 
hypertonic saline injection or non-fatiguing ischemic exercise. There would be more structural 
damage at the location of the muscle during delayed onset muscle soreness as well as less local 
pain stimulus. Sidhu et al. [113, 114] have shown how these same type III/IV afferents play a role 
in inhibiting the motor cortex during fatiguing exercise whereas during non-fatiguing exercise they 
cause excitation. This indicates a differential influence of these afferent fibres on the nervous 
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system during differing conditions, which may also be at play during delayed onset muscle 
soreness.  
In the current study, DOMS significantly increased the cortical silent period compared to 
no DOMS. This suggests in the presence of DOMS or type III/IV afferent activation there is an 
increase in intracortical inhibition. These results may lead to some support of the conclusions by 
Mercier et al., [118] when they attempted to determine if sensorimotor integration, the interaction 
of pain afferents and motor output, occurred via the process of short afferent inhibition (SAI) in 
the cortex. Briefly, SAI is peripheral nerve stimulation paired with single TMS activation of the 
motor cortex, resulting in an inhibition of TMS activation of muscle response for a few 
milliseconds after the sensory volley reaches the cortex.  Their results showed cutaneous heat pain 
applied to the hand resulted in decreased cortical excitability but did not result in any significant 
difference in SAI between the pain and neutral conditions, indicating that the interaction between 
pain/sensory and motor pathways is not mediated by direct rapid pathways and must involve higher 
order integrative areas [118]. Recent findings on DOMS have determined that at 48 hours post-
exercise, Mmax amplitude in the biceps brachii muscle, elicited by brachial plexus stimulation 
were no different than pre-DOMS levels [128]. This supports that DOMS related consequences 
are not likely related to reductions in action potential generation and propagation in the motor unit 
[142]. Similarly, our findings resulted in no significant difference in Mmax area between DOMS 
and no DOMS. Thus, there appears to be a strong corticospinal contribution to DOMS-related 
impairments.  
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Topical Analgesic gel reduces pain 15, 30 and 45 minutes’ post application 
A significant difference from pre-values was found at the 15,30 and 45-minute post gel 
application time points for the pressure-pain threshold measurement for the topical analgesic 
group. This difference was nonexistent in the placebo group and establishes support for menthol 
(the medicinal ingredient in the analgesic gel) as a topical analgesic substance that helps to reduce 
perceived pain. We hypothesized that this change in pain measures would be consistent with 
alterations in CSE. Similarly, Johar et al. [82] found that menthol significantly reduced DOMS 
compared to ice application, and that tetanic force was higher in the menthol group compared to 
the ice group, probably due to a decreased pain sensation following the application of the topical 
analgesic. This reduction in perceived pain would be due to the activation of the main receptor of 
menthol, (TRMP8) [132] on a subpopulation of afferents that have TRP receptors present. 
Activation stimulates a central synaptic release of glutamate (Glu) from these TRP specific 
afferents, this glutamate is thought to bind to Group II or III mGluR receptors on the presynaptic 
muscle damage-activated nociceptive afferents or possibly postsynaptically on dorsal-horn 
neurons, which causes attenuation of pain sensation [120]. This attenuation would presumably 
nullify the effect of the A-delta/c fibres on the nervous system causing less presynaptic inhibition, 
and in turn, increase motor output even in the presence of nociceptive muscle damage. However, 
this does not seem to be the case, it is possible the TRMP8 cascades through a different pathway 
of afferents to cause analgesia or the Type III/IV afferents have differing inhibition properties 
while mGluR receptors are bound. Our results showed no excitation and slight indication of 
inhibition of neurophysiological properties in cortical regions due to the analgesic gel in the 
presence of DOMS. Furthermore, in experiment A (No DOMS) no significant differences in 
neurophysiological measures were found across any time point throughout the experiment, 
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indicating a lack of effect on the analgesic gel on cortical or spinal excitability when there is no 
DOMS present. 
The application of topical analgesic to a biceps brachii with DOMS increases intracortical  
 
inhibition. 
  
Cortical silent period significantly increased 30 minutes and 45 minutes after the 
application of analgesic gel, this increase was not present in either the placebo group in experiment 
B or either group in experiment A. In terms of its underlying physiology, the CSP is believed to be 
generated by both spinal inhibitory mechanisms (e.g., recurrent inhibition, refractoriness of spinal 
motoneurones, post-synaptic inhibition) and inhibitory intracortical interneurons within M1 [130, 
143]. Previously, it has been accepted that the duration of the CSP is influenced primarily by 
cortical mechanisms [130]. In particular, γ-aminobutyric acid (GABA)-ergic interneurons in the 
cortex (i.e., GABAB receptors) were thought to mediate the CSP [144, 145]. However, a recent 
study by Yacyshyn et al. has discovered a substantial spinal influence on CSP. This would indicate 
that only in the presence of DOMS/type III/IV afferent activation, does the stimulation of TRPM8 
receptors cause an increased nervous system inhibition either spinally or cortically. We proposed 
that the activation of these receptors would cause an increase in motor output due to less afferent 
input from the nociceptive fibres, but in fact, this interaction caused further inhibition while still 
decreasing pain perception. This would indicate a clear interaction of the afferent fibres affected 
by menthol and those through which DOMS act on.  
Conclusion 
 
In conclusion DOMS had an inhibitory effect on both supraspinal and spinal derived motor 
output when compared to the no DOMS group. Furthermore, the application of the topical 
analgesic gel resulted in increased pressure-pain threshold, indicating a reduced pain perception at 
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15, 30 and 45 minutes’ post application and increased cortical inhibition, as measured by an 
increased CSP, at 30 and 45 minutes post application. These changes only occurred in the presence 
of DOMS. The application of topical analgesic in the absence of DOMS resulted in no significant 
effect on CSE, indicating that the topical analgesic has an effect on the central nervous when 
applicant is experiencing DOMS and helps alleviate the individual’s DOMS associated perceived 
pain. 
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Tables 
Table 1. Baseline demographic values. Data are expressed as Mean (Standard Deviation).  
*, statistically significant difference, p < .05. 
 
Experiment A: No DOMS 
Demographic 
Topical Analgesic 
(n = 8) 
Placebo 
(n = 8) 
p-value 
(Topical Analgesic 
vs. Control) 
Age 
(yr) 
25 (6.4) 26 (3.9) .545 
Mass 
(kg) 
79.3 (8.1) 84.5 (9.8) .619 
Height 
(cm) 
180.2 (6.1) 179.5 (6.5) .340 
Sex 
(n) 
F = 3 M = 5 F = 5 M = 3 .317 
Experiment B: DOMS 
Demographic 
Topical Analgesic 
(n = 8) 
Placebo 
(n = 8) 
p-value 
(Topical Analgesic 
vs. Control) 
Age 
(yr) 
25 (6.4) 26 (3.9) .710 
Mass 
(kg) 
79.3 (8.1) 84.5 (9.8) .267 
Height 
(cm) 
180.2 (6.1) 179.5 (6.5) .838 
Decrease in Torque 
(%) 
34.9 (22.7) 31.1 (21.1) .735 
Experiment A: No DOMS Versus Experiment B: DOMS 
Demographic 
Experiment A -  
No DOMS 
(n = 16) 
Experiment B -  
DOMS 
(n = 16) 
p-value 
(Experiment A vs. 
Experiment B) 
Age 
(yr) 
23 (1.1) 26 (5.1) *.037 
Mass 
(kg) 
71.9 (9.1) 81.9 (9.1) *.004 
Height 
(cm) 
174.2 (8.2) 179.8 (6.1) *.035 
Sex 
(n) 
F = 8 M = 8 F = 0 M = 16 *.001 
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Table 2. Raw data values for neurophysiological outcome measures in Experiment A: No 
DOMS. The p-value column indicates between-group (topical analgesic, n = 8; control, n = 8) 
comparisons of baseline outcome measures. MEP, motor evoked potential; Mmax, maximal 
compound motor unit action potential; CMEP, cervicomedullary evoked potential.  
 
Outcome 
Measure 
Group 1 -  
Topical Analgesic 
(n = 8) 
Group 2 -  
Control 
(n = 8) 
p-value 
(Pre-) 
MEP Area 
(MEP/Mmax Ratio) 
Mean (SD) Mean (SD)   
Pre-Gel 0.243 (0.195) 0.202 (0.150) .647 
5 min Post-Gel 0.211 (0.144) 0.192 (0.171) ─ 
15 min Post-Gel 0.239 (0.207) 0.185 (0.150) ─ 
30 min Post-Gel 0.170 (0.102) 0.210 (0.186) ─ 
45 min Post-Gel 0.174 (0.097) 0.170 (0.119) ─ 
MEP Latency 
(ms) 
          
Pre-Gel 12.29 (1.73) 11.69 (1.35) .455 
5 min Post-Gel 11.74 (1.06) 10.59 (1.91) ─ 
15 min Post-Gel 11.72 (0.68) 11.22 (1.66) ─ 
30 min Post-Gel 11.41 (0.73) 10.80 (2.39) ─ 
45 min Post-Gel 11.69 (0.95) 12.43 (1.28) ─ 
Silent Period 
(ms) 
          
Pre-Gel 89.74 (19.44) 65.08 (36.60) .115 
5 min Post-Gel 92.14 (17.96) 60.66 (26.24) ─ 
15 min Post-Gel 95.63 (20.30) 71.37 (43.72) ─ 
30 min Post-Gel 91.48 (18.57) 76.01 (32.03) ─ 
45 min Post-Gel 94.90 (19.57) 69.19 (41.39) ─ 
CMEP Area 
(CMEP/Mmax Ratio) 
          
Pre-Gel 0.200 (0.172) 0.172 (0.130) .717 
5 min Post-Gel 0.148 (0.086) 0.125 (0.075) ─ 
15 min Post-Gel 0.146 (0.107) 0.122 (0.079) ─ 
30 min Post-Gel 0.127 (0.086) 0.134 (0.075) ─ 
45 min Post-Gel 0.124 (0.082) 0.137 (0.099) ─ 
CMEP Latency 
(ms) 
          
Pre-Gel 7.44 (1.33) 7.85 (1.34) .943 
5 min Post-Gel 7.76 (0.87) 8.36 (2.08) ─ 
 70 
15 min Post-Gel 7.58 (1.01) 8.37 (2.26) ─ 
30 min Post-Gel 7.95 (1.32) 8.20 (1.76) ─ 
45 min Post-Gel 7.72 (1.24) 8.21 (1.18) ─ 
Mmax Area 
(mV·s) 
          
Pre-Gel 0.07 (0.06) 0.07 (0.03) .920 
5 min Post-Gel 0.08 (0.06) 0.08 (0.04) ─ 
15 min Post-Gel 0.08 (0.06) 0.08 (0.04) ─ 
30 min Post-Gel 0.08 (0.06) 0.07 (0.04) ─ 
45 min Post-Gel 0.08 (0.06) 0.08 (0.04) ─ 
Mmax Latency 
(ms) 
          
Pre-Gel 4.21 (0.98) 5.30 (1.86) .164 
5 min Post-Gel 5.57 (3.39) 5.14 (1.32) ─ 
15 min Post-Gel 4.36 (1.06) 5.29 (1.28) ─ 
30 min Post-Gel 4.45 (1.05) 5.40 (1.87) ─ 
45 min Post-Gel 4.40 (0.94) 4.92 (2.46) ─ 
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Table 3. Raw data values for neurophysiological outcome measures and pressure pain threshold 
in Experiment B: DOMS. The p-value column indicates between-group (topical analgesic, n = 8; 
control, n = 8) comparisons of baseline outcome measures. MEP, motor evoked potential; 
Mmax, maximal compound motor unit action potential; CMEP, cervicomedullary evoked 
potential; PPT, pressure pain threshold; DOMS, delayed-onset muscle soreness. *, statistically 
significant difference from pre-gel value (p < .05). ǂ, statistically significant difference from pre-
DOMS value (p < .05). 
 
Outcome 
Measure 
Group 1 -  
Topical Analgesic 
(n = 8) 
Group 2 -  
Control 
(n = 8) 
p-value 
(Pre-) 
MEP Area 
(MEP/Mmax Ratio) 
Mean (SD) Mean (SD)   
Pre-Gel 0.075 (0.036) 0.118 (0.068) .132 
5 min Post-Gel 0.092 (0.060) 0.150 (0.076) ─ 
15 min Post-Gel 0.089 (0.049) 0.140 (0.075) ─ 
30 min Post-Gel 0.088 (0.055) 0.134 (0.074) ─ 
45 min Post-Gel 0.081 (0.044) 0.136 (0.085) ─ 
MEP Latency 
(ms) 
          
Pre-Gel 12.54 (1.35) 12.17 (1.18) .574 
5 min Post-Gel 12.86 (1.14) 12.26 (0.78) ─ 
15 min Post-Gel 12.95 (1.18) 12.72 (1.20) ─ 
30 min Post-Gel 12.94 (1.52) 12.62 (0.87) ─ 
45 min Post-Gel 12.96 (1.62) 12.48 (0.89) ─ 
Silent Period 
(ms) 
          
Pre-Gel 85.67 (19.65) 116.03 (36.36) .057 
5 min Post-Gel 93.20 (28.14) 118.87 (30.85) ─ 
15 min Post-Gel 83.57 (16.41) 118.10 (37.90) ─ 
30 min Post-Gel *96.08 (26.62) 111.50 (41.73) ─ 
45 min Post-Gel *94.23 (22.32) 110.47 (41.04) ─ 
CMEP Area 
(CMEP/Mmax Ratio) 
          
Pre-Gel 0.056 (0.039) 0.098 (0.044) .061 
5 min Post-Gel 0.058 (0.042) 0.113 (0.051) ─ 
15 min Post-Gel 0.069 (0.035) 0.101 (0.037) ─ 
30 min Post-Gel 0.059 (0.032) 0.100 (0.041) ─ 
45 min Post-Gel 0.061 (0.042) 0.097 (0.047) ─ 
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CMEP Latency 
(ms) 
          
Pre-Gel 7.95 (0.97) 8.93 (2.53) .325 
5 min Post-Gel 7.99 (0.99) 9.00 (2.82) ─ 
15 min Post-Gel 7.77 (0.84) 8.23 (1.02) ─ 
30 min Post-Gel 7.84 (0.68) 8.20 (0.88) ─ 
45 min Post-Gel 7.80 (0.90) 8.14 (1.00) ─ 
Mmax Area 
(mV·s) 
          
Pre-Gel 0.10 (0.04) 0.10 (0.05) .738 
5 min Post-Gel 0.09 (0.04) 0.10 (0.05) ─ 
15 min Post-Gel 0.09 (0.04) 0.09 (0.04) ─ 
30 min Post-Gel 0.09 (0.04) 0.10 (0.05) ─ 
45 min Post-Gel 0.09 (0.05) 0.10 (0.05) ─ 
Mmax Latency 
(ms) 
          
Pre-Gel 4.58 (0.33) 4.77 (0.38) 0.320 
5 min Post-Gel 4.75 (0.53) 4.82 (0.81) ─ 
15 min Post-Gel 6.63 (0.43) 4.67 (0.27) ─ 
30 min Post-Gel 4.57 (0.46) 4.68 (0.35) ─ 
45 min Post-Gel 4.65 (0.39) 4.56 (0.28) ─ 
PPT 
(kg) 
          
Pre-DOMS 7.03 (2.48) 5.77 (2.35) .315 
Pre-Gel ǂ3.12 (1.26) ǂ3.51 (1.58) .370 
5 min Post-Gel 3.40 (1.37) 3.66 (2.07) ─ 
15 min Post-Gel *3.70 (1.69) 3.69 (1.87) ─ 
30 min Post-Gel *3.92 (1.67) 3.77 (2.21) ─ 
45 min Post-Gel *4.33 (1.65) 4.12 (2.32) ─ 
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Table 4. Baseline (pre-gel) raw data values for neurophysiological outcome measures in 
Experiment A: No DOMS versus Experiment B: DOMS. The p-value column indicates between-
experiment (No DOMS, n = 16; DOMS, n = 16) comparisons of baseline outcome measures. *, 
statistically significant difference, p < .05. MEP, motor evoked potential; Mmax, maximal 
compound motor unit action potential; CMEP, cervicomedullary evoked potential.  
 
Outcome 
Measure 
Experiment A -  
No DOMS 
(n = 16) 
Experiment B -  
DOMS 
(n = 16) 
p-value 
(Pre-) 
MEP Area 
(MEP/Mmax Ratio) 
Mean (SD) Mean (SD)   
Pre-Gel 0.222 (0.169) 0.097 (0.057) *.011 
MEP Latency 
(ms) 
          
Pre-Gel 11.99 (1.53) 12.36 (1.23) .468 
Silent Period 
(ms) 
          
Pre-Gel 77.41 (31.05) 100.85 (32.29) *.045 
CMEP Area 
(CMEP/Mmax Ratio) 
          
Pre-Gel 0.186 (0.148) 0.077 (0.045) *.012 
CMEP Latency 
(ms) 
          
Pre-Gel 7.46 (1.29) 8.44 (1.92) .100 
Mmax Area 
(mV·s) 
          
Pre-Gel 0.073 (0.045) 0.099 (0.041) .093 
Mmax Latency 
(ms) 
          
Pre-Gel 4.75 (1.54) 4.67 (0.356) .844 
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Figure Legends 
Figure 1. Experimental Set-up for (A) experiment A: No DOMS and (B) experiment B: DOMS.  
 
Figure 2. Comparisons of motor evoked potential (MEP)-related findings across topical 
analgesic gel (black circles) and placebo gel (white circles) groups (n = 8 each), from Experiment 
A: No DOMS (A, C) and Experiment B: DOMS (B, D). Panels A and B depict MEP area 
normalized to maximal compound motor unit action potential (Mmax) area for Experiments A 
and B, respectively. Panels C and D show silent period for Experiments A and B, respectively. 
Data are expressed as ratios of post-gel time-points (5, 15, 30, 45 min post-gel application) to 
pre-gel. Circles represent mean and error bars represent the standard error of the mean. *, 
statistically significant compared to pre-gel value, p < .05. 
 
Figure 3. Comparisons of cervicomedullary evoked potential (CMEP)-related findings across 
topical analgesic gel (black circles) and placebo gel (white circles) groups (n = 8 each), from 
Experiment A: No DOMS (A) and Experiment B: DOMS (B). Panels A and B indicate CMEP 
area normalized to maximal compound motor unit action potential (Mmax) area for Experiments 
A and B, respectively. Data are expressed as ratios of post-gel time-points (5, 15, 30, 45 min 
post-gel application) to pre-gel. Circles represent mean and error bars represent the standard 
error of the mean. 
 
Figure 4. Comparisons of pressure-pain threshold-related findings across topical analgesic gel 
(black circles/bars) and placebo gel (white circles/bars) groups (n = 8 each), from Experiment B: 
DOMS. Data in the larger plot are expressed as ratios of post-gel time-points (5, 15, 30, 45 min 
post-gel application) to pre-gel. Circles in the larger plot represent mean and error bars represent 
the standard error of the mean. Data in the inset are expressed as ratios of pre-DOMS to pre-gel. 
Bars in the inset represent mean and error bars represent the standard error of the mean. *, 
statistically significant compared to pre-gel value in the topical analgesic gel group, p < .05. ǂ, 
statistically significant compared to pre-gel value in the placebo gel group. 
 
Figure 5. Comparisons of neurophysiological outcomes across Experiment A: No DOMS (left) 
and Experiment B: DOMS (right). Panels A and B show ratios of motor evoked potential (MEP) 
area and cervicomedullary evoked potential (CMEP) area normalized to maximal compound 
motor unit action potential (Mmax) area, respectively. Panel C shows silent period. Data are 
expressed as pre-gel values for the entire sample of each experiment (n = 16 each). Columns 
represent the grand mean and error bars represent the standard error of the mean. *, statistically 
significant compared to Experiment A, p < .05. 
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Figure 1. 
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